Drug approvals, clinical research, and emerging therapies — with the context behind each story, not just a headline and a link.
Congo’s Ebola outbreak has surpassed 4,000 deaths among 8,300 cases, with containment efforts hampered by unpaid health workers, repeated strikes, and the burning of an Ebola transit camp near Bunia. An MSF aid worker was evacuated to the Netherlands, while mobile labs are cutting diagnostic turnaround from 72 hours to six.
Read original →This preprint presents a single-nucleus multi-omic atlas spanning 459,856 transcriptomic and chromatin-accessibility profiles from 21 adult human tissues and four donors. It catalogs over 1 million candidate cis-regulatory elements, maps cCRE-gene associations, and uses sequence-to-function models to score 548,656 fine-mapped variants, offering a reference framework for interpreting non-coding genetic risk and tissue-specific gene regulation.
Read original →The FDA approved Fayuvi, an Ultragenyx gene therapy for Sanfilippo syndrome type A, an ultra-rare disease sometimes called childhood Alzheimer's. It is the first drug specifically approved to treat Sanfilippo, offering families a treatment option where previously they mainly received supportive care advice; pricing was not immediately released.
Read original →Pennsylvania has reported a fourth measles-associated death, an 18-year-old with a rare neurological complication, as the state's outbreak approaches 700 cases and the U.S. faces its worst measles year since 1991. None of the four deceased were vaccinated, and officials cite falling vaccination coverage, access problems, and misinformation as the outbreak grows.
Read original →Scholar Rock received FDA approval for Isembyld, the first therapy targeting muscle loss in spinal muscular atrophy (SMA). The drug is indicated for adults and children 2 years and older already receiving SMN2-targeting SMA therapies, based on a late-stage trial showing improved motor skills when added to an SMN2-targeting drug.
Read original →Novartis' experimental cardiovascular drug pelacarsen failed to reduce cardiovascular events in a Phase 3 trial, a major blow to efforts targeting the Lp(a) risk factor.
Read original →eGenesis announced that two of the first recipients of its gene-edited pig kidneys have gone on to receive successful human kidney transplants, providing early evidence that a prior xenograft does not preclude a subsequent human-to-human transplant. The patients required months of dialysis after the pig organs were removed, but their time free of dialysis marks a milestone for the field of xenotransplantation, which aims to address the shortage of human donor organs.
Read original →Ionis won FDA approval for Zanvastro, the first disease-modifying therapy for Alexander disease, after a pivotal trial showed treated patients' walking speed stayed stable while controls declined 33%.
Read original →Revolution Medicines' daraxonrasib (Rasonque) received FDA approval for metastatic pancreatic cancer, but shares stayed flat despite the historic milestone. The approval follows Phase III data showing median overall survival nearly doubled versus chemotherapy.
Read original →FDA approved daraxonrasib (Rasonque) from Revolution Medicines for advanced pancreatic cancer, the first drug targeting a genetic cause of the disease. In a trial, second-line treatment nearly doubled median overall survival to 13.2 months versus 6.7 months for chemotherapy, marking a major advance.
Read original →Pennsylvania reported the first two U.S. measles deaths of the year, both in unvaccinated individuals, as the country faces its worst measles outbreak since 1991 amid falling vaccination rates and federal policy changes.
Read original →The FDA has again paused Regenxbio's gene therapy trial for Hunter syndrome after small masses were found on the spines of five patients. The patients are asymptomatic, but the pause follows a prior brain tumor case linked to the same AAV gene therapy platform, raising fresh safety concerns.
Read original →Moderna and Merck revealed that a 1,137-patient trial of their mRNA cancer vaccine reduced melanoma recurrence after surgery, surprising even their own executives. The result validates the mRNA approach but still faces skepticism pending full data.
Read original →This STAT+ newsletter leads with Merck and Moderna reporting the first successful late-stage trial of a personalized mRNA cancer vaccine, a potential breakthrough in oncology, and also headlines a story on expert scrutiny of Huidagene's disclosures after a patient death.
Read original →STAT's Morning Rounds newsletter reports that Merck and Moderna's personalized mRNA cancer vaccine slowed melanoma in a late-stage trial, and also covers a potential shift in public health accreditation standards on equity, a study showing youth-oriented marketing for cannabis products, and a profile of an immunologist who grew up unvaccinated.
Read original →Moderna and Merck announced that their personalized mRNA cancer vaccine, intismeran, combined with Keytruda slowed melanoma recurrence and spread in a late-stage trial, marking the first randomized Phase 3 success for neoantigen vaccines.
Read original →The FDA approved Bristol Myers Squibb's oral multiple myeloma treatment iberdomide (Zenbexus), marking the debut of a new drug class and the first approval using a more sensitive remission measure.
Read original →President Trump signed an executive order that overhauls federal vaccine recommendations, cutting the childhood vaccine schedule from 18 to 11 shots and proposing to split the MMR vaccine, despite lacking scientific evidence. The order shifts vaccine policy authority from scientists to presidential advisers and faces expert criticism over feasibility and safety.
Read original →The FDA granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), an engineered oncolytic viral therapy used with nivolumab, for patients with advanced melanoma that has progressed on PD-1 inhibitors. In a clinical trial, one in four patients responded, with responses lasting a median of nearly 14 months, offering a new option for this difficult-to-treat population.
Read original →The FDA approved Orzeyful (oveporexton), the first drug to treat the full range of narcolepsy type 1 symptoms by directly restoring orexin signaling. In two placebo-controlled trials, it improved wakefulness and reduced cataplexy and other symptoms. Common side effects include insomnia and increased urination.
Read original →FDA licensed Ezplaz Freeze Dried Plasma, the first freeze-dried plasma product in the U.S., for adult transfusion when other plasma products are unavailable. It is room-temperature-stable and rapidly reconstituted, making it suitable for emergency and remote settings, including military and disaster response.
Read original →President Trump announced that more than 20 million seniors will receive a one-time $90 payment in October to help cover Medicare Part B premiums, funded through the Medicare Improvement Fund. The move, unveiled on social media just ahead of the Nov. 3 midterms, adds to a series of pre-election cash pledges — including $500 ACA rebate checks and a proposed $5,000 payment to every American adult — and marks an unusual use of a fund previously tapped by Congress for other priorities.
Read original →New national Medicaid data show that after a 2016 American Academy of Pediatrics push to offer addiction medications to young patients, more adolescents and young adults with opioid use disorder did start buprenorphine or methadone — but the increase was small and six-month retention may have actually fallen. The JAMA Network Open study of nearly 230,000 patients ages 13 to 25 highlights how steeply minors are still blocked from these highly effective treatments.
Read original →Pennsylvania has confirmed 943 measles cases — about a quarter of the 2026 U.S. total — and a fifth death, but public health officials say the true size of the outbreak is unknown and possibly unknowable because only confirmed cases are reported. The gap is attributed largely to underreporting in Amish communities with low vaccination rates and limited interaction with the wider health system.
Read original →A STAT analysis of NIH spending finds the agency again spent its full ~$34 billion external grants budget but funded only about 58,000 projects in the most recent fiscal year, down from 61,000 a year earlier and ~63,700 before the second Trump administration. Researchers report that opaque, delayed grant review is slowing their work and undermining innovative science, while the administration's stated goals of geographically even funding and expanded early-career support saw little progress.
Read original →A bioRxiv preprint reports that tumor-associated macrophages (TAMs) rely on the high-affinity folate receptor FRβ (encoded by Folr2) to take up folate in the low-folate tumor microenvironment, a dependency that sustains their immunosuppressive function. Using a novel Folr2-/- mouse model and patient metabolomics, the authors show that losing FRβ repolarizes TAMs to pro-inflammatory states, increases cytotoxic T and NK cell infiltration, and slows tumor growth through a cGAS-STING-dependent mechanism.
Read original →Researchers introduce force-probe coupled steered molecular dynamics (fp-SMD), a simulation framework that models an optically trapped bead and biomolecule together to overcome the timescale mismatch in single-molecule force spectroscopy. Applied to a cholesterol–β-cyclodextrin host-guest complex, fp-SMD reproduces experimental rupture-force histograms and reveals force-dependent pathway switching underlying catch-slip behavior.
Read original →A multicenter study developed an automated, explainable, NCCT-based machine-learning decision-support system for spontaneous intracerebral hemorrhage by combining CT radiomics with clinical variables. In 2,680 patients, the integrated model improved functional outcome prediction and prognostic risk stratification over conventional models, with external validation AUC 0.86.
Read original →A medRxiv preprint reports that Olink proteomic risk models trained in UK Biobank for 15 diseases achieve strong predictive accuracy and largely generalize to FinnGen and All of Us, though performance varies by disease. The authors find phenotyping quality, rather than demographic, ancestry, or technical factors, is the likely main driver of cross-cohort variability.
Read original →This bioRxiv preprint systematically investigates how receptor-binding affinity/avidity and catalytic payload activity jointly determine immunotoxin selectivity. Attenuating payload catalytic activity improved selectivity between receptor-high and receptor-low cells, and in vivo increased the maximum tolerated dose of a HER2-targeted immunotoxin by 400-fold while enabling antitumor activity at tolerated doses.
Read original →A large real-world medRxiv study across MoleMap clinics in New Zealand and Australia found that AI decision support in nurse-led teledermoscopy screening was associated with higher malignancy detection (25.5 vs 15.7 per 1,000 lesions) and more intervention and safety-netting recommendations. Because allocation was not randomised, the findings are associational and need prospective, outcome-based confirmation.
Read original →Medicare Advantage insurers including UnitedHealth and Humana are raising enrollee out-of-pocket costs and cutting dental and other benefits for 2027, according to federal data analyzed by STAT and investment firms. The changes could surprise seniors during the annual enrollment period starting Oct. 15, especially if their doctors or broad-network plans are dropped. Insurers are seeking higher profits after investor dissatisfaction with margins, even after winning a payment increase and delayed Trump administration reforms in April.
Read original →Science published a special issue on women's health, edited by an all-female team, that spotlights menopause, pain, and sex-dependent biology beyond reproduction. It argues that women remain poorly represented in clinical trials and that political attacks and funding cuts threaten women-specific research.
Read original →In a STAT opinion piece, transplant surgeon Babak J. Orandi argues that data on GLP-1 use in children with obesity are reassuring: a study found a 310-fold rise in prescriptions for ages 8–11 since 2019, yet only 0.6% of more than 3.5 million children with obesity received one, and 94% of recipients had severe obesity. He says FDA approval for younger children could improve coverage and reduce disparities, but should be balanced against unknown long-term effects on growth and puberty.
Read original →Upcoming midterm elections are poised to reshape two key Senate committees with jurisdiction over health care. Both the Finance and health committees could see major changes, including significant Republican turnover on Finance, with at least five of its 14 GOP members set to leave.
Read original →Sanofi and Regeneron have expanded their long-running partnership, announcing a new collaboration to develop antibodies for immunological diseases after the success of Dupixent. Sanofi will pay Regeneron $1 billion upfront, with up to $7 billion in additional milestones, while Regeneron leads R&D and Sanofi handles commercialization, splitting profits evenly.
Read original →Cryo-EM structures show that the anti-CB1 antibody Nimacimab inhibits human CB1 through extracellular allosteric stabilization rather than orthosteric blockade, and that it cooperates with orthosteric antagonists. The work also reveals how JD5037 remodels the CB1 extracellular vestibule for peripheral selectivity, providing a structural framework for peripherally selective CB1 therapeutics.
Read original →SEEKER is a genome-scale library-on-library screening platform that pairs TCRs and peptide-MHCs in single cells to decode T cell antigen recognition. Screening CD8+ T cells from HLA-B*27+ ankylosing spondylitis patients validated 53 TCR-peptide pairs and revealed extensive cross-recognition and polyreactive T cells, suggesting virus-triggered autoimmunity in multi-organ autoimmune diseases.
Read original →Researchers developed Methylation-associated Gene Expression (MaGE) predictors, whole-blood DNA methylation proxies for p14ARF, p16INK4A, and p21CIP1 expression plus a composite score, as a scalable non-invasive measure of cellular senescence. In Generation Scotland (n=18,859), MaGE identified 45 Bonferroni-significant associations across 18 incident diseases and all-cause mortality, with disease-specific links for p21 and p16, and tracked severity and treatment response in Crohn's disease. It may enable population-scale senescence research and patient stratification in senolytic trials.
Read original →A medRxiv preprint describes a time-aware machine learning approach that uses cardiotocography (CTG) features across labor to identify fetuses at risk of hypoxic-ischemic encephalopathy (HIE), instead of focusing only on the final hour before delivery. In 174,186 Kaiser Permanente Northern California deliveries, extending the training window and adding time from labor onset improved early detection, identifying 40.3% of HIE cases at least 3 hours before delivery. The authors argue intrapartum AI should shift from end-of-labor diagnosis to early-warning decision support.
Read original →The Trump administration finalized a Medicare drug-pricing rule for physician-administered drugs, applying its GLOBE most-favored-nation pilot to only four companies and exempting drugmakers with voluntary Medicaid MFN deals. The rule is far weaker than initially proposed, with projected savings 96% lower, while the related GUARD pilot remains proposed.
Read original →A federal judge declined to dismiss an investor lawsuit alleging UnitedHealth Group inflated its 2024 earnings by $3.3 billion to hide weakness in its Medicare Advantage business, though most of CalPERS’s other claims were dismissed as non-actionable puffery. The surviving central claim concerns allegations that UnitedHealth made Medicare Advantage patients appear sicker to obtain more government payments.
Read original →Hundreds of thousands of legally present immigrants — including refugees, asylees, sex-trafficking victims, and Afghan interpreters — are set to lose Medicaid coverage starting Oct. 1 under the One Big Beautiful Bill Act, according to state data collected by KFF Health News. More than 281,000 enrollees across nine states and D.C. are already identified as at risk, suggesting the law's coverage impact is broader than anticipated.
Read original →Eli Lilly’s mid-stage trial combining Zepbound with the amylin-targeting candidate eloralintide produced significantly greater weight loss in people with obesity and type 2 diabetes, but high discontinuation rates may raise tolerability questions. The highest-dose combination led to 23.3% weight loss after 48 weeks, beating Zepbound alone and eloralintide alone.
Read original →Experts agree that kratom and its potent derivative 7-OH need regulation, but they are split on how to do it. The DEA has proposed temporarily placing high-potency 7-OH in Schedule I while leaving milder natural kratom products largely unregulated, a move critics say could harm dependent users and hinder research. Pressure for action has increased after two University of Mississippi students died this month, though authorities have not said kratom contributed to either death.
Read original →A STAT opinion piece by UC Davis cell biologist Paul Knoepfler examines a new Nature study from Stanford's Sergiu Pașca lab that created mice with a cortex made of human brain cells. Knoepfler says the work goes beyond earlier human stem-cell injections into mouse brains and raises profound questions about consciousness and human-animal chimeras.
Read original →A genome-scale ORF screen in retinal pigment epithelium cells identified protective factors against oxidative stress, including the cardiac transcription factor NKX2-5. An engineered NKX2-5ΔHD variant restored visual and electrophysiological function in middle-aged mice and improved systemic measures of frailty, suggesting unbiased resilience-factor screening can yield reengineered therapeutics for age-related decline.
Read original →A nested case-control study within a prospective twin-pregnancy cohort identified early maternal plasma protein signatures of preeclampsia that outperform conventional singleton markers, which did not differ between cases and controls. A model combining annexin A2, annexin A3, chitotriosidase-1, FTL, and maternal clinical factors achieved an AUC of 0.97 for early twin preeclampsia discrimination.
Read original →A new bioRxiv study uses 231 haplotype-resolved human pangenomes with matched long-read multi-omics to analyze polymorphic transposable element alleles, moving beyond fixed insertions to capture sequence, epigenetic, and transcript variation. It finds that segregating TEs can gain, remodel, or lose regulatory function, with methylation and transcript context shaping effects and selection acting on presence and absence alike.
Read original →A medRxiv preprint reports that rare CSMD2 variants—biallelic missense, monoallelic frameshift, and de novo missense—are associated with neurodevelopmental disorders including autism, ADHD, developmental delay/intellectual disability, and brain anomalies. Functional and zebrafish data support CSMD2 haploinsufficiency and a role for CSMD2 in neurodevelopment, expanding the CSMD paralog family's link to autosomal recessive and dominant NDD.
Read original →Researchers identify an operon in Bacillus subtilis in which EndoV, an endonuclease V, repairs uracil DNA lesions caused by the secreted cytidine deaminase toxin YwqJ, providing protection even when the cognate immunity protein YwqK is absent. This DNA-repair-based defense also limits replication of PBS1, a bacteriophage whose genome naturally substitutes uracil for thymine. The work suggests DNA repair can act as a distinct layer of immunity within toxin-immunity loci, linking interbacterial antagonism and antiviral defense.
Read original →A medRxiv analysis of FDA adverse event reports finds that uveitis linked to the BCMA×CD3 bispecifics teclistamab and elranatamab includes a late infectious form, mainly cytomegalovirus chorioretinitis, shared across T-cell-redirecting bispecifics, and an early immune-mediated form signaled only for elranatamab. The findings suggest clinicians should assess visual symptoms promptly and rule out CMV retinitis before starting corticosteroids.
Read original →PhRMA has named Eric Cantor, a former GOP House majority leader, as its next CEO. He will lead the brand drug industry's top lobbying group at a time of mounting political pressure on drug prices from both parties, including Trump administration efforts to codify voluntary pricing agreements and Democratic interest in most-favored-nation pricing for Medicare.
Read original →A biotech news roundup leads with AstraZeneca's $2 billion investment in Summit Therapeutics, alongside Novo Nordisk's $2.6 billion licensing deal with China's Hengrui Pharma for an oral obesity drug, positive early data from Invivyd and Immix Biopharma, and mixed four-year results for UniQure's Huntington's gene therapy.
Read original →UniQure reported that its one-time gene therapy AMT-130 continued to slow Huntington’s disease progression four years after surgical brain implantation, but the benefit appears to have diminished compared with a year earlier. The high-dose analysis showed a 44% slowing versus external controls, though the difference was not statistically significant, raising durability questions as the FDA reviews UniQure’s marketing application.
Read original →The MAHA Institute, a think tank formed by allies of HHS Secretary Robert F. Kennedy Jr., held an event urging broader sharing of patient health data with federal researchers, especially to study chronic disease origins. Kennedy called for aggregating immunization, clinical, lab, pharmacy, and claims data from state exchanges, EHRs, Medicare, Medicaid, and commercial sources, while privacy and ethics concerns and Nebraska's CyncHealth partnership remain central flashpoints.
Read original →This STAT News opinion piece argues that historic SNAP cuts have already stripped food assistance from at least 1.5 million children and could drive more family separations by worsening poverty-related child protective services involvement. It cites H.R. 1’s estimated $187 billion SNAP reduction over eight years and research linking food insecurity to higher child maltreatment investigations, urging material support instead of surveillance.
Read original →STAT reports that manufacturers have recently announced FDA breakthrough device status for a range of products—including abdominal CT triage algorithms, UTI diagnostic panels, and thrombectomy robots—just before an October cutoff. CMS has finalized the removal of Medicare payment pathways that since 2020 allowed breakthrough-designated devices to qualify for new technology add-on and transitional pass-through payments without proving substantial clinical improvement or novelty, so future designees will no longer receive that special reimbursement treatment.
Read original →A medRxiv preprint uses open ecological, genomic, and digital behavioral data to trace the 2026 MV Hondius Andes virus outbreak to the southern-Andean region where the principal rodent reservoir lives, rather than a Tierra del Fuego landfill. The index case was documented in that transmission focus shortly before the likely exposure period, helping prioritize further epidemiological investigation.
Read original →A large Mexico City Prospective Study analysis of 47,123 men and 97,589 women found a J-shaped association between HDL cholesterol concentration and all-cause mortality in men and a U-shaped association in women, driven by different causes of death. Small HDL particle count was linked to lower all-cause, cardiovascular, and other mortality in both sexes, a novel finding that requires confirmation.
Read original →A bioRxiv preprint reports that ADAMTS-mediated proteolysis of versican (VCAN) and its matrikine versikine regulate tumor tertiary lymphoid structure (TLS) formation and predict immunotherapy response in metastatic colorectal cancer. The work links a wound-healing/germinal-center matrix modification to dendritic-cell activation, progenitor-exhausted CD8+ T-cell engagement, and therapeutic efficacy of versikine in tumors with weak VCAN proteolysis.
Read original →This bioRxiv preprint shows that after traumatic brain injury, blood-brain barrier leakage occurs focally at cerebral microthrombi, where endothelial cells adopt a Cav-1-enriched transcriptional program driving transcytosis of blood proteins. Genetic deletion of Cav-1 reduces leakage, immune-cell diapedesis, microglial activation, and neuronal loss, while endothelial Cav-1 re-expression restores leakage. The findings link post-traumatic microvascular thrombosis to secondary neuronal injury and suggest targeting Cav-1-dependent transcytosis as a therapeutic strategy.
Read original →A study of the 2023 Maui wildfires found that metal mixtures in lingering smoke, ash, and debris were linked to lung-health harms in nearby residents up to a year and a half after the fires. The findings suggest post-wildfire air quality and contaminated soil and soot need longer-term monitoring and recovery planning.
Read original →Merck has discontinued Recarbrio, a last-resort antibiotic for serious hospital infections, from the U.S. market without explanation. The move underscores concerns about large pharmaceutical companies' commitment to antibiotics, where last-resort status limits commercial potential.
Read original →The Trump administration has asked the Supreme Court to let it enforce, for now, restrictions on gender-affirming care in federal prisons after lower courts blocked the policy. The policy halts surgeries, hormone therapy and social accommodations such as wigs while continuing mental health therapy; the ACLU argues withholding medically necessary care violates inmates' rights and constitutes cruel and unusual punishment.
Read original →STAT+ reports that AbbVie has won FDA approval for a Parkinson’s disease pill. The same newsletter roundup covers Kodiak Sciences’ Phase 3 equivalence data for Zenkuda, Merck’s $400 million upfront licensing deal with SciBrunch for a KRAS G12D cancer drug, and Novo Nordisk’s shift toward marketing GLP-1 obesity drugs as consumer products.
Read original →An opinion piece argues that AI is eroding the specialized expertise barriers that have long kept biological weapons rare, pointing to Anthropic's report of five blocked misuse cases and warnings from Harvard and RAND that AI could broaden the pool of actors capable of large-scale biological attacks. It says frontier-lab safeguards and open-weight models differ sharply, and that slowing AI development is only useful if paired with biodefense efforts.
Read original →Researchers developed an XGBoost classifier using 42 genetic and biochemical features to discover novel type VI secretion system effectors, screening 2,559 bacterial genomes and identifying 19,958 candidates. They validated three new effectors, including a peptidoglycan-degrading enzyme and a putative metalloprotease, expanding the known T6SS effector repertoire.
Read original →A medRxiv preprint combines the largest-to-date liver fat GWAS with a meta-analysis of MASH randomized trials to argue that liver fat reduction is causally linked to better liver outcomes and could serve as a surrogate endpoint. Genetic and trial evidence showed that lower liver fat was associated with reduced cirrhosis and hepatocellular carcinoma odds, as well as higher MASH resolution and fibrosis improvement.
Read original →Researchers developed a probabilistic framework to estimate biological age gap (BAG) and biological age uncertainty (BAU) in more than 450,000 UK Biobank participants, showing that uncertainty is a distinct dimension of aging. Higher BAU independently predicted mortality, loss of healthspan, and multimorbidity, with molecular and genetic analyses linking it to inflammation, metabolic regulation, tissue remodelling, and immune/lipid-metabolic processes.
Read original →A large-scale human genomic analysis of mitochondrial dynamics genes links the fusion factor OPA1 to hepatic fibrosis in MASLD/MASH, with OPA1 transcripts and protein progressively dysregulated as fibrosis advances. In mice, hepatocyte-specific OPA1 loss triggered stellate cell activation, zone 3 fibrosis, circulating mito-DAMPs, and worsened experimental MASH, identifying OPA1 as a central regulator connecting mitochondrial homeostasis to fibrosis.
Read original →Researchers introduce SpiderNet, an interpretable representation-learning framework that discovers directed cell-cell meta-interactions (MIs) from spatial transcriptomics. In simulations and more than 5.8 million profiled cells, it recovers known communication programs and uncovers cancer- and aging-associated relays, including a pan-cancer COLLAGEN-linked fibroblast-tumor program linked to poorer survival and immunotherapy non-response. The work proposes MIs as a reusable organizational layer connecting molecular interactions to tissue phenotypes.
Read original →A new bioRxiv preprint reports a mouse model enabling temporal control of mitochondrial mutagenesis, showing that mtDNA mutations arising in the first two months of life are sufficient to drive diverse age-related pathologies. The severity is governed by tissue-specific selective pressures, and manipulating mitochondrial fusion can modulate selection against deleterious variants, suggesting early-life events may set the pace of aging and that fusion-targeted interventions could slow or reverse pathogenic expansion.
Read original →The Trump administration is canceling nearly $1 billion in congressionally approved spending through a rare "pocket rescission," mostly targeting HHS programs for refugees and unaccompanied minors plus diversity-related initiatives. The move, condemned by Senate Appropriations Chair Susan Collins and called illegal by GAO, escalates a broader executive-branch effort to erode Congress's power of the purse.
Read original →Researchers identify a feed-forward read-write mechanism by which UHRF1 binds its own mono-ubiquitinated H3 products to promote H3 multi-mono-ubiquitination and recruit DNMT1. Disrupting this reading activity accelerates DNA methylation loss in late-replicating, CpG-sparse regions linked to partially methylated domains in cancer and aging, suggesting UHRF1's ubiquitin reading safeguards vulnerable methylome regions.
Read original →Eli Lilly has won approval for a once-weekly insulin shot, a notable advance for diabetes treatment convenience. The same STAT newsletter roundup also covers a $90 million jury award to Nektar Therapeutics over Lilly's handling of the autoimmune drug rezpeg, and FDA commissioner nominee Heidi Overton's evasive Senate confirmation hearing.
Read original →At least five candidates are competing to become the next WHO director-general, a role facing unprecedented challenges due to the U.S. withdrawal and shrinking global health funding. The election is considered the most consequential in modern WHO history, with the successor taking office in August 2027.
Read original →A new Rutgers study in JAMA Network Open found that 97% of 175,000 public comments on the FDA’s proposed menthol cigarette ban were form letters opposing the rule, with nearly half matching tobacco industry campaigns. The campaign is notable because the FDA delayed its rule, and the proposal later collided with Biden re-election politics.
Read original →Former NCHS leaders criticize Health and Human Services Secretary Robert F. Kennedy Jr.'s policy that the CDC will report measles-caused deaths only when the National Center for Health Statistics confirms measles as the underlying cause, arguing it will delay real-time outbreak surveillance. The change is creating confusion amid Pennsylvania's reporting of four measles-associated deaths and more than 800 cases, while the CDC dashboard lists just one measles-related death with an asterisk.
Read original →Using more than 50,000 sequenced M. tuberculosis isolates, researchers identified polyketide synthase 12 (pks12) as exceptionally essential during human infection and validated it in zebrafish and mouse models. Loss of pks12 severely disrupted the host-facing surface and arabinoglycan architecture, an amplified effect explained by the newly discovered lipid MPMMM, which is made at higher abundance by antigen 85 mycolyltransferases. The work establishes a host-facing genomic-metabolomic-phenotypic approach for discovering in vivo essential TB genes that shape the Mtb-host interface.
Read original →Indonesia’s Constitutional Court struck down a two-year-old amendment that had allowed patent evergreening, reinstating a prohibition on the pharma industry tactic. Patient advocates say the ruling sends an important message to other countries to challenge the practice and protect access to medicines.
Read original →STAT's Morning Rounds newsletter reports the U.S. is experiencing its worst outbreak of a highly contagious disease since 1991, and the CDC has added a measles death to its online counter. The roundup also previews Heidi Overton's FDA commissioner confirmation hearing, the White House shelving a controversial NIH executive order, and radiologists' rapid embrace of AI.
Read original →A physician and epidemiologist who survived a near-fatal measles infection in 1961 warns that the current U.S. measles surge is preventable and dangerous, with cases at their highest since 1991 and deaths reported in Pennsylvania. He emphasizes that MMR vaccination remains highly effective, but falling childhood vaccination rates and access barriers are driving the outbreak.
Read original →Congress is considering the first major overhaul of Medicare physician payment in more than a decade, with bipartisan agreement on the outlines. The leading proposal would tie doctor pay rates to a medical inflation measure, guaranteeing pay increases but rolling back Medicare’s volume-control and value-based care priorities.
Read original →STAT profiles Heidi Overton, a physician from rural New Mexico who once planned to return to her hometown of Gallup to practice medicine. Instead, she has become the youngest-ever nominee to lead the FDA, with her medical degree, rural roots, and calm, reasoned style central to her rise.
Read original →In a STAT opinion piece, preventive cardiologist Vishal Khetpal argues that recent Phase 3 disappointments—Novartis's pelacarsen for lipoprotein(a) and Novo Nordisk's ziltivekimab for IL-6 inflammation—show that hitting a validated biological target did not translate into fewer cardiovascular events. The results raise hard questions for preventive cardiology's precision-medicine push.
Read original →Heidi Overton, President Trump's nominee to lead the FDA, appeared before a Senate committee today for a highly anticipated hearing. If confirmed at 37, she would be the youngest FDA commissioner ever, taking over an agency recovering from politicized decisions and a nearly 20% staff reduction. Lawmakers and industry leaders have scrutinized her lack of managerial experience and her alignment with Health Secretary Robert F. Kennedy Jr.'s policies, including changes to the childhood vaccine schedule.
Read original →A bioRxiv study used a high-throughput splicing assay to test 640 rare deep intronic variants from 76 patients with recessive inherited retinal diseases, finding that 98 variants activated cryptic exons and were classified as pathogenic. The functional assay confirmed diagnoses for 64% of patients and revealed that SpliceAI predicted only 6.6% of pathogenic variants, suggesting many undiagnosed cases may be due to intronic mutations missed by current prediction tools.
Read original →Researchers identified a prefrontal-hypothalamic circuit in monkeys that bidirectionally controls heart rate: stimulating ventral ventrolateral prefrontal area a12 slows the heart and raises heart-rate variability, while inactivating a12 or its lateral hypothalamic projections raises heart rate. The work also introduces an ultrasound-based sonogenetic method for cell-type-specific circuit control and links the same prefrontal region to risky decision-making, suggesting a target for cognitive-autonomic dysregulation.
Read original →A bioRxiv study reports that histotripsy, a non-invasive focused ultrasound technique that mechanically disrupts solid tumors via cavitation, induces vascular normalization and remodeling in treated and contralateral off-target tumors. The effect is antigen-specific and mediated in part by CXCR3+CD8+ T cells, and it enhances tumor perfusion and intratumoral delivery of chemotherapy and therapeutic monoclonal antibodies, supporting histotripsy combinations with systemic therapy.
Read original →A planned executive order that would have given White House political appointees veto power over NIH grants is reportedly “looking dead” after bipartisan backlash, including a letter from Senate Appropriations Chair Susan Collins. The episode marks another congressional check on OMB’s efforts to tighten political control over federal biomedical research funding.
Read original →Heidi Overton, President Trump’s nominee to lead the FDA, plans to tell a Senate committee that the agency must move faster and more efficiently to compete with China’s growing biotech industry. She says she will continue Operation Trialblazer to speed clinical trials and streamline drug development.
Read original →An FDA advisory panel voted to endorse Galleri, Grail's blood test for multi-cancer screening, concluding its benefits outweigh its risks. The panel was unanimous on safety but split on effectiveness, and the FDA often follows such recommendations though it is not obligated to.
Read original →Anthropic has formed a life sciences research group and lab to use Claude for fundamental biology, including mining DNA datasets, generating hypotheses at scale, and testing them in the lab. In early results, Claude autonomously discovered a novel enzyme system associated with an array of DNA repeats, reminiscent of CRISPR, based on a reverse transcriptase from a jumbo phage. The system's function is unknown, but its features match programmable systems that cut, copy, and paste DNA, and CRISPR pioneer Feng Zhang reviewed the preprint.
Read original →Quorum Health, a private equity-owned chain of mostly rural hospitals, is converting into a nonprofit and taking all 11 of its hospitals with it. The move could bring tax and 340B drug-pricing advantages and redirect cash to patient care, but the article asks whether it is really a bailout for investors after Quorum's 2020 bankruptcy and renewed insolvency risk.
Read original →An Estonian national-scale retrospective observational study built a digital atlas of recorded care patterns for 1,080 ICD-10 diagnostic categories using 2012–2024 health records from a 30% random sample. It generated 3,240 diagnosis-window summaries across 509,856 people and used language-model classification plus expert review to assess diagnosis–concept relationships, supporting clinical orientation, hypothesis generation, and observational study planning.
Read original →A medRxiv preprint evaluates a multilingual ambient AI scribe and finds that individually safe transcription and note-generation layers can produce higher clinician-facing note risk, especially in complex or low-resource-language encounters. The authors conclude safety evaluation must include the final note rather than relying on component-level metrics alone.
Read original →A secondary analysis of the NHS-Galleri trial estimated potential five-year life-years from the stage IV reductions seen during two incident screening rounds. It projected 466 potential life-years per million people screened annually, while cautioning that the conditional estimate is not evidence of mortality reduction.
Read original →A medRxiv preprint reports that the splicing factor SRRM4 is elevated in vascular smooth muscle cells from human and mouse abdominal aortic aneurysms and promotes disease by alternatively splicing REST into a non-functional REST4 isoform, thereby modulating VSMC phenotype through STAT1. VSMC-specific SRRM4 silencing attenuated aneurysm formation, and STAT1 inhibition reduced AAA progression in mice, suggesting a new REST/STAT1 therapeutic axis for AAA.
Read original →HHS announced a second round of initiatives this year to reduce animal testing in drug development. The FDA finalized a rule allowing non-animal methods when "appropriate" for drug and biologic safety, while NIH pledged $88 million for 10 infrastructure projects to advance new approach methodologies like cell-based assays, organs-on-a-chip, and computer models.
Read original →Brian Blase, president of the Paragon Health Institute and a trusted adviser to congressional Republicans, is defending the sweeping Medicaid cuts he supported, arguing that backlash overlooks the case for them. The cuts, enacted through the One Big Beautiful Bill Act to offset tax cuts, are projected to reduce Medicaid spending by about $1 trillion over the coming decade and could cause 7 million people to lose coverage, according to preliminary CBO estimates.
Read original →A multi-ancestry GWAS in the NIH All of Us Research Program compared mild (N=14,372) and moderate-to-severe (N=7,096) asthma against non-asthma controls (N=28,816), finding shared risk loci alongside distinct genetic architectures for each phenotype. The results support existing biologic targets and point to new therapeutic candidates, especially innate/steroid-resistance pathways in severe disease.
Read original →In a fibromyalgia trial and a knee osteoarthritis cohort, motor cortex pain compensation was found to be a modifiable state whose analgesic efficiency depends on allostatic load, and a burden-adjusted neurophysiological index predicted rehabilitation response. The findings suggest the same motor cortex signal can carry different clinical meaning under high versus low allostatic load and may be restored by rehabilitation.
Read original →A medRxiv preprint reports that dysfunctional cysteine metabolism is uniquely linked to severe COVID-19 in cancer patients, and that N-acetylcysteine supplementation improved outcomes in a prospective trial by reducing suppressive monocyte-T cell interactions and boosting CD8+ T cell responses. The findings support cysteine supplementation as a potential strategy for reversing redox-driven immune dysfunction in high-risk cancer patients with severe respiratory viral infection.
Read original →A population-based Quebec cohort study compared COVID-19 burden in adults with systemic autoimmune rheumatic diseases (SARDs) versus immunocompetent adults with or without comorbidities over March 2020–April 2023. Despite similar adjusted infection rates, people with SARDs had substantially higher adjusted risks of hospitalization and ICU admission/death across pandemic phases, with the highest risks among those on rituximab or mycophenolate. The authors conclude SARD patients should be prioritized in future public health emergencies.
Read original →This prospective multi-country cohort evaluated the diagnostic accuracy of WHO IMCI visual inspection for neonatal jaundice versus transcutaneous bilirubinometry in community settings. Among 14,331 infants across six sites in Asia and Africa, visual inspection at 3-5 days had only 16% sensitivity despite 96% specificity, with 56% positive and 86% negative percent agreement. The authors conclude that better affordable screening tools are urgently needed for neonatal hyperbilirubinemia in low-resource settings.
Read original →Several members of Congress are opposing a reported White House plan to create a commission of political appointees that would review and sign off on all NIH grants. The proposal, pushed by OMB Director Russell Vought and reportedly directed by President Trump after NIH Director Jay Bhattacharya refused to cut Harvard funding, would require unanimous board decisions and has escalated tensions over political control of federal biomedical research funding.
Read original →Grail shares surged 33% Monday after FDA documents posted ahead of a Wednesday advisory committee meeting suggested the agency may view its Galleri multi-cancer early detection blood test favorably. FDA approval would be expected to help secure Medicare and other insurer reimbursement, though the agency is not required to follow the panel's recommendation.
Read original →STAT+ reports that Eli Lilly’s breast cancer combination has won approval. The same newsletter roundup covers radiopharma consolidation after an FDA rejection, Novo’s pipeline expansion, an early ADHD signal for orexin agonists, and a call to double NIH funding.
Read original →Addiction clinics across the U.S. are reporting a sharp rise in patients seeking treatment for withdrawal from kratom and especially concentrated 7-hydroxymitragynine (7-OH) products. At Boulder Care, kratom-related patients rose from 3% of new admissions in September 2025 to 14% in August 2026, while other clinics now treat 10-20 such patients weekly. The trend coincides with FDA and DEA moves to restrict 7-OH, though clinicians say the withdrawal can be as severe as that from fentanyl or oxycodone.
Read original →ARCHER-LD is a GPU-accelerated method for computing genome-wide linkage disequilibrium (LD) directly from biobank-scale datasets instead of relying on external reference panels. It achieves large speedups over PLINK and computes the full LD matrix for ~120 million variants in under six hours on 512 A100 GPUs, with the Python/CuPy tool publicly released.
Read original →A medRxiv preprint presents the first lifespan normative reference charts for EEG beta oscillations (N=22,094, ages 1–100), showing that beta power follows a tri-phasic trajectory peaking near age 50 and that aperiodic 1/f adjustment reverses apparent developmental trends in beta frequency. The work also maps disorder-specific beta deviations across seven neurological and neuropsychiatric conditions, arguing that unadjusted beta biomarkers systematically distort both lifespan maturation and clinical signatures.
Read original →Researchers identify GPR182, an atypical chemokine receptor family lipoprotein receptor, as a key mediator of LDL deposition in aortic endothelial cells during atherosclerosis. In mouse models, genetic depletion or monoclonal antibody blockade of GPR182 reduced aortic lipid uptake and protected against plaque progression without changing circulating cholesterol, suggesting GPR182 inhibition as a potential therapy.
Read original →HealthFlux is a pan-modal world model trained on UK Biobank data to learn a single latent state of human health, integrating clinical records, omics, and imaging. It predicts 195 diseases and death over five years with a mean AUROC of 0.816, beating the previous state of the art (0.715) and specialized risk scores, and generalizes to diseases never seen in training.
Read original →Telix Pharmaceuticals is acquiring ITM Isotope Technologies Munich in a deal worth at least $1.65 billion, with up to $700 million more contingent on ITM’s lead drug meeting regulatory and sales goals. The merger creates a larger competitor in radiopharmaceuticals, a field currently dominated by Novartis, and the headline says it follows a surprise FDA rejection for one of the companies.
Read original →AlphaGenome Atlas is a genome-wide resource that predicts regulatory effects for essentially every human single nucleotide variant and many observed indels, condensing them into a unified AVI score. It achieved state-of-the-art benchmark performance, helped solve a rare epileptic encephalopathy case, and increased power to detect non-coding variants underlying population phenotypes, improving prioritization and interpretation of non-coding variation.
Read original →A bioRxiv study using post-implantation mouse embryos and the dTAG degradation system challenges the classic bivalency model, showing H2Aub rather than H3K27me3 is the primary transcriptional silencer. It defines a hierarchical repression architecture in which H3K27me3 and H3K9me3 reinforce H2Aub-mediated silencing, and links disruption of this system to retinoic acid–FGF signaling defects, somitogenesis arrest, and severe organogenesis defects.
Read original →A bioRxiv study shows that plaque-associated microglia in Alzheimer's disease mount a TREM2-dependent anabolic program linking protein synthesis to mitochondrial biogenesis, which—not the DAM signature—marks phagocytic competence. This program is self-limiting, peaking at low amyloid burden and declining as disease progresses, and is conserved in humans across 523 donors, suggesting anti-amyloid antibodies may risk biosynthetic exhaustion.
Read original →A bioRxiv preprint reports single-neuron recordings from 3,506 neurons in 97 patients performing a recognition memory task with false memories, identifying two classes of memory-selective cells. One class signals pattern separation, and population activity predicts true memory in the hippocampus versus choice in pre-supplementary motor area, suggesting a cellular basis for distinguishing similar memories.
Read original →In a medRxiv preprint, researchers use primary open-angle glaucoma as a model to show that impaired regulatory T-cell immune tolerance can actively drive neurodegeneration. Transfer of patient-derived immune cells caused retinal ganglion cell loss in humanized mice without raising intraocular pressure, and expanding regulatory T cells protected vision and axons in an experimental model. The findings suggest immunoregulatory therapy could complement pressure-lowering treatments in glaucoma.
Read original →Researchers constructed HuDeHA, an integrated single-cell atlas of the developing human hippocampus comprising 658,059 cells from post-conceptional week 3 to 15.3 years, and used it to benchmark iPSC-derived brain organoids carrying the familial Alzheimer's disease variant PSEN1 E280A. The organoids showed altered cellular composition, cross-lineage transcriptional changes, and a shift toward mature neuronal states, positioning HuDeHA as a reference for developmental benchmarking of hippocampus-relevant models.
Read original →In a mouse model of Marinesco-Sjögren syndrome, neonatal intracerebroventricular AAV-PHP.eB delivery of SIL1 prevented ataxia and muscle pathology, with Purkinje-cell-specific restoration sufficient to rescue motor performance. The findings offer preclinical proof-of-principle for AAV-mediated SIL1 gene therapy in a rare disorder with no disease-modifying treatment.
Read original →A large GWAS of blood pressure traits in 140,559 admixed adults from the Mexico City Prospective Study uncovers many ancestry-specific genetic signals and highlights the value of diverse populations in genetic discovery.
Read original →A large medRxiv study of women over 70 finds that associations between menopause hormone therapy (MHT) and late-life cognition/brain health vary by MHT formulation and APOEε4 status. Estradiol-based MHT was linked to more favorable cognitive and neuroimaging outcomes in APOEε4 carriers than conjugated equine estrogens, suggesting menopause care should account for both formulation and genetic risk.
Read original →A new bioRxiv study combining phylogenomic analysis of clinical Mycobacterium tuberculosis strains from Vietnam and Peru with engineered isogenic strains shows that insertions/deletions in simple sequence repeats—including homopolymer and trinucleotide repeats—are highly variable, correlate with clinical antibiotic resistance, and can directly reduce drug potency. In particular, a prevalent ppe53 CGC deletion causes intermediate resistance to isoniazid, rifampicin, and streptomycin by shortening a polyalanine stretch and impairing processing and secretion of the full-length protein.
Read original →Researchers identified TDP-43 as a regulator of circular RNA biogenesis and found that its dysfunction in ALS/FTD induces cryptic circular RNAs (c-circRNAs). Rolling-circle amplification assays distinguished TDP-43 pathology in human CNS tissue with a 0.99 AUC, and c-circUNC13A tracked with UNC13A cryptic exon suppression, suggesting a target-engagement biomarker for emerging UNC13A-directed therapies.
Read original →A bioRxiv study tracked Burkholderia multivorans evolution in chronic cystic fibrosis infections across eight patients over 7–17 years, finding that divergent strains converged on similar phylogenetic and mutational patterns. The emergence of a dominant bacterial lineage, more than any specific mutations, was associated with faster lung function decline, suggesting pathogen evolutionary dynamics may help predict CF disease progression.
Read original →A bioRxiv preprint shows that loss of TDP-43 function in human neurons triggers widespread changes in circular RNA (circRNA) biogenesis, particularly upregulation of cryptic circRNAs that incorporate intronic cryptic exons. These circRNAs are more stable than their linear RNA counterparts, accumulate progressively in neurons, and are elevated in postmortem brain tissue from ALS, FTD, and Alzheimer's disease patients, suggesting they serve as stable molecular signatures of TDP-43 dysfunction.
Read original →A medRxiv modeling study using enhanced surveillance in Uvira, Democratic Republic of the Congo, estimates that a 2020 mass oral cholera vaccination campaign reaching 66% coverage averted 56% of infections and deaths over three years, equivalent to about 2,350 facility-attended cases and 44 deaths. The findings suggest imperfect coverage, population turnover, and high transmission limited the campaign's full potential, so cholera control will also require water and sanitation interventions.
Read original →A bioRxiv study shows that METTL3 promotes human coronavirus OC43 replication independently of interferon signaling, with METTL3 inhibition reducing viral gene expression and life cycle progression. The findings suggest m6A modification of viral RNA directly supports coronavirus replication and highlight METTL3 as a potential antiviral target.
Read original →A bioRxiv preprint uses sex-biased differential expression across 1,494 donors in three brain cell types to empirically estimate statistical power in single-cell studies. It finds that small-effect genes are systematically underpowered even at 600 donors, that reducing sequencing depth and cell counts can eliminate over half of detected DEGs, and that only the top quartile of significant genes were reproducible under standard multiple-testing thresholds. The authors recommend cell-type enrichment, deeper sequencing, better powering, and stricter significance thresholds.
Read original →This STAT News report from Sudan describes how civil war attacks on hospitals have collapsed the health system, forcing patients with cancer and other long-term illnesses to make dangerous journeys for care. It focuses on cervical cancer patient Fatouma Mahdi Ahmed Saeed, who traveled hundreds of miles to Dr. Tom Catena's Mother of Mercy Hospital in the Nuba Mountains, and on the broader toll of 205 attacks on health facilities and mass displacement.
Read original →A new medRxiv analysis of Nigeria's 2023–24 Demographic and Health Survey built the first national hepatitis B mother-to-child prevention cascade. Although 72% of mothers attended antenatal care, only 12.3% were tested for hepatitis B there, and just 55% of infants received the birth-dose vaccine—far below WHO elimination targets, with testing lowest in the highest-burden North-West.
Read original →A large bioRxiv spatial multi-omics study profiled over 112 million cells across three neoadjuvant immune checkpoint blockade regimens in melanoma, mapping tumor microenvironment features that distinguish response from resistance. It introduces three computational pathology tools and links mature tertiary lymphoid structures/germinal centers to disease-free survival, including regimen-specific differences and 3D structures missed by standard histopathology.
Read original →This bioRxiv preprint uses somatic genetics to show that human memory NK cells undergo clonal selection after cytomegalovirus infection, with dominant clones marked by coherent receptor/chromatin states and somatic mutations. It identifies loss-of-function KMT2D mutations as one genetic influence on NK-cell fitness and proposes clonal selection as an organizing principle of innate immune memory.
Read original →Researchers developed a human myelin microphysiological system (myelin MPS) that generates 96 models per well plate by culturing neural organoids on 3D-printed directional microfibers with oligodendrocyte progenitor cells. The platform reproduced MS-like demyelination from patient immune cells and distinguished treatment responder/nonresponder profiles, offering a scalable human model for individualized multiple sclerosis drug testing.
Read original →Health Secretary Robert F. Kennedy Jr. used a keynote at the Children's Health Defense conference to renew vaccine-safety attacks, citing a hepatitis B vaccine package insert to question FDA approval standards and linking vaccines to chronic illness. STAT notes the insert's own causality caveat and evidence that universal newborn hepatitis B vaccination cut chronic infections by 99%, while the Trump administration ended that policy last year.
Read original →Researchers reported in Science that a very rare genetic variant is associated with 25-fold higher odds of lung cancer, particularly relevant to never-smokers. The variant is far more common in Southern Appalachia, though experts say it likely explains only a small share of never-smoker lung cancer cases; the finding may still inform screening and treatment strategies and highlights discoveries from large genetic datasets like 23andMe.
Read original →Health Secretary Robert F. Kennedy Jr. appointed eight new members to the U.S. Preventive Services Task Force, reviving a panel that has been effectively dormant with no meetings for over a year. The picks include five medical specialists rather than generalist clinicians, prompting concerns from the AMA about the loss of primary care representation on a body that determines which preventive services insurers must cover.
Read original →A group of 17 researchers is suing the NIH, alleging that its practice of screening grant applications and existing grants for certain words and phrases violates their First Amendment rights. The class action seeks to halt the term-based screening, which has targeted research on diversity, health disparities, climate change, and vaccines under the Trump administration.
Read original →Canakinumab, an anti-IL-1β monoclonal antibody, was associated with reduced HIV reservoir in people with HIV alongside distinct whole-blood gene expression signatures: Cana_Up genes in CD4/CD8 T cells linked to cell cycling and antigen presentation, and Cana_Down genes in CD14+ monocytes linked to inflammatory and epigenetic pathways. The findings suggest IL-1β blockade may recondition immunity by reversing monocyte dysfunction and enhancing HIV-specific CD4/CD8 effector function, providing a mechanistic rationale for targeting the HIV reservoir.
Read original →Researchers developed FutureFlu, a framework that quantifies influenza variant fitness by combining molecular genetic divergence, immune escape, and population transmission dynamics to predict dominant strains for seasonal vaccine selection. Validated across 24 seasons, it recommended antigenically matched strains more often than current annual recommendations, especially for A/H3N2 and B/Victoria, and outperformed existing methods with or without HI antigenic data. An open platform now provides real-time predictions to supplement WHO vaccine recommendations.
Read original →Montana's SB535 creates a state pathway for physicians to give experimental, post-Phase 1 drugs outside clinical trials, with a state-registered private review board (ETRB) providing oversight. The law is notable because it lets sponsors and clinics charge for access, which the author argues fixes the broken risk-reward that stalls drug developers in the "Valley of Death" after Phase 1.
Read original →Pennsylvania reported two more measles-related deaths, bringing the U.S. to four this year — the most since 1992 — amid an outbreak with 693 cases across 38 counties. Health secretary Robert F. Kennedy Jr. disputed measles’ role in the first two deaths, and the CDC has not yet recorded any measles-related deaths for 2026. The same STAT newsletter also covers Democratic midterm health-oversight plans, political rhetoric on dementia, and a physician who teaches using his own cancer experience.
Read original →A STAT health-policy newsletter reports that HHS Secretary Robert F. Kennedy Jr. will keynote the anti-vaccine Children's Health Defense conference, his first public embrace of the group since taking over HHS. The same roundup covers Senate confirmation hearings for HHS nominees, the absence of Trump's FDA pick from the witness list, and House health care bill activity.
Read original →Newly released documents show that Medicare's AI-driven prior authorization pilot, WISeR, was rolled out hastily and with errors. The program requires providers in six states to get approval before certain procedures and will run until 2031, and one vendor warned CMS that its launch timeline was unrealistic.
Read original →A federal judge in Massachusetts issued a preliminary injunction blocking the Department of Homeland Security from imposing a four-year cap on visas used by graduate students and postdoctoral researchers, preserving the duration-of-status policy while a lawsuit proceeds. The ruling found the rule likely failed to comply with the Administrative Procedure Act and could have major implications for the U.S. biomedical workforce, which relies heavily on international researchers.
Read original →Abbott Laboratories agreed to pay $385 million to settle claims tied to a 2022 contamination investigation at its Sturgis, Michigan, infant formula plant, whose closure contributed to nationwide formula shortages. The settlement resolves Justice Department, state attorney general, and relator lawsuits without Abbott admitting fault, and Abbott says government testing of unopened product was negative for Cronobacter sakazakii.
Read original →Health Secretary Robert F. Kennedy Jr. will deliver a keynote at a Children's Health Defense conference in Washington this week, publicly embracing the anti-vaccine group he founded and chaired until late 2024. The appearance is his first such embrace since taking over HHS, underscoring CHD's unprecedented access to federal power despite Kennedy's earlier Senate promise not to discourage Americans from getting vaccines.
Read original →STAT's Pharmalittle roundup reports that AstraZeneca's camizestrant failed a pivotal first-line trial in advanced breast cancer, potentially limiting a drug recently granted accelerated U.S. approval, and that the FDA approved Scholar Rock's Isembyld as the first therapy targeting muscle loss in spinal muscular atrophy. It also references a Novo name change and other industry news.
Read original →This STAT Morning Rounds newsletter reports a third measles-related death in Pennsylvania amid a 676-case outbreak, with the CDC rebuking the state's response. It also covers a modeling study warning that Trump administration most-favored-nation drug deals could cut Medicare savings by up to 80%, and rural hospital leaders' disillusionment with a $50 billion rural health fund.
Read original →Researchers present an implantable epidural focused ultrasound (eFUS) device that uses a 2D piezoelectric array integrated on a custom ASIC to deliver electronically steerable deep brain neuromodulation in freely moving rats. The device achieved accurate acoustic steering in vitro and, when targeting the ventral tegmental area, increased dopamine release in the nucleus accumbens with no inflammatory markers, though mild tissue damage occurred at the epidural placement. The approach is intended to enable chronic, continuous, multi-site neuromodulation beyond the episodic stimulation possible with transcranial low-intensity focused ultrasound.
Read original →A new analysis suggests the projected savings from the Trump administration’s most-favored-nation Medicare drug pricing plan could be cut by as much as 80% because of secretive deals with more than two dozen drugmakers. The plan aims to tie Medicare prices to those in 19 other wealthy countries and claims $26 billion in savings, but the administration’s GLOBE and GUARD pilot programs may be undermined by those deals.
Read original →U.S. health officials declared an end to the largest cyclospora outbreak in U.S. history, linked to recalled iceberg lettuce from Taylor Farms grown in central Mexico, with nearly 13,000 cases tied to the multistate outbreak. The outbreak contributed to nearly 20,000 lab-confirmed U.S. cyclospora cases since May 1—more than 16 times last year's count—and two deaths in Michigan, though the contamination's origin remains unclear. The FDA ended on-site inspections in Mexico and said samples are pending analysis, while the episode highlights reduced international produce inspections.
Read original →The Centers for Medicare and Medicaid Services issued guidance allowing states to use a tier system to determine which Medicaid recipients are medically frail and exempt from a 20-hour-per-week work or volunteer requirement. The approach may reduce paperwork for the sickest patients by automatically exempting severe diagnoses, but experts and advocates warn it remains complex and could still cause very ill people to lose coverage as millions are projected to leave Medicaid.
Read original →A Pennsylvania coroner confirmed that two measles-related infant deaths in Lancaster County last month involved newborns, with measles itself killing one 6-week-old girl and being listed as a contributing factor in the other infant’s death. The findings have intensified a national political fight over the outbreak, vaccine messaging, and whether the CDC will officially count the deaths as measles-associated.
Read original →ARPA-H plans to commit up to $62.7 million to its ADVOCATE program to develop partially autonomous, FDA-authorized AI tools for treating heart failure. The first awards go to Atman Health, UpDoc, Tempus AI, and teams from Stanford, Duke, and Kaiser Permanente, with $33.7 million committed in year one.
Read original →In a STAT First Opinion essay, Ezekiel J. Emanuel and Abe Baker-Butler argue that autonomous AI will surpass both unaided and AI-assisted physicians at five core cognitive medical tasks by 2030, citing a JAMA analysis of studies published since January 2024. They use the 19th-century antiseptic debate and President Garfield’s death to warn that regulatory and physician resistance, not lack of evidence, is the main obstacle.
Read original →STAT+ headlines the FDA's approval of an AstraZeneca breast cancer drug, though the excerpt gives no further specifics. The same newsletter issue also covers standout mid-stage results from Roivant, a funding round for Moonwalk, and access complications involving Revolution Medicines' pancreatic cancer drug.
Read original →Reynolds American has begun selling four new fruit-flavored Vuse Pro vapes without FDA authorization, a move critics blame on the FDA's softened enforcement guidance from May. The launch may trigger broader industry noncompliance and intensify the debate over flavored e-cigarette regulation.
Read original →Rural and independent hospitals are increasingly seeking mergers with larger health systems to survive looming Medicaid funding cuts from Trump's tax bill, a trend that could reshape U.S. health care access and costs.
Read original →Researchers present Botanic1, a family of plant genomic language models trained via self-supervision, capable of processing DNA sequences from hundreds of base pairs up to 128 kbp. The models outperform existing generalist and plant-specific genomic models across a wide range of plant evaluation tasks at a smaller computational budget, and will be released for research use.
Read original →The FDA removed the 30-year monitoring program for clozapine in February 2025, but the author argues that fear among clinicians remains the real barrier to using this effective antipsychotic, especially in children with schizophrenia.
Read original →Seattle scientists, led by Nobel laureate David Baker, have launched a $95 million AI biology accelerator aimed at using artificial intelligence to map nature's design rules.
Read original →The Justice Department has joined a lawsuit seeking to dismantle key parts of Section 504 of the Rehabilitation Act, a landmark disability-rights law, signaling that HHS will no longer enforce the community integration mandate. If successful, the action could upend decades of legal precedent favoring community-based care over institutionalization.
Read original →The FDA has launched the TEMPO pilot, provisionally allowing some developers of generative AI medical devices, including Cadence and Limbic, to market their products before formal authorization—an experiment aimed at supporting Medicare's ACCESS model and testing AI regulation in real-world settings.
Read original →Eli Lilly is acquiring Merida Biosciences for up to $2.9 billion, expanding beyond obesity into immune-mediated diseases. Merida's biologic drugs selectively degrade pathogenic autoantibodies, targeting disease causes rather than broadly suppressing immunity.
Read original →FDA clears Stryker's surgical cockpit, a system that integrates Apple's Vision Pro VR headset for use in surgical settings, marking a step forward for consumer VR in medicine.
Read original →An opinion piece argues that the Trump administration has increased bureaucratic burdens on scientists and health care, despite promises of efficiency. It highlights the NIH's use of computer scans for prohibited terms, falling grant award rates, and an OMB proposal to let political appointees override peer review.
Read original →President Trump announced nine new drug pricing deals with pharmaceutical companies, expanding his administration's voluntary agreements to lower U.S. drug costs. The deals include pledges to match foreign prices, offer Medicaid most-favored-nation rates, and contribute to medical stockpiles, with some companies avoiding tariffs in return.
Read original →The mRNA technology behind Covid-19 vaccines, after a period of political whiplash, is receiving a boost from successful clinical trials of Moderna and Merck's personalized mRNA melanoma vaccine. Experts hope the success may help reduce vaccine skepticism and stabilize the field's future.
Read original →The FDA approved rusfertide, developed by Protagonist Therapeutics and marketed by Takeda as Mimrylo, for the rare blood cancer polycythemia vera, which causes excess red blood cell production.
Read original →The FDA has granted Juul Labs permission to sell Juul2, an updated e-cigarette with optional age-verification technology. The decision marks Juul's first new device in over a decade and comes after billions in lawsuit settlements over teen use. Regulators say the device can help adult smokers quit, though it is not an approval or endorsement.
Read original →At a federal autism advisory committee meeting, members explicitly blamed vaccines for autism, revisiting a debunked theory, and approved a research plan that shifts funding away from genetics to less evidence-backed areas like diet and folate. The committee was reshaped by RFK Jr., who also faces scrutiny over his role in the Samoa measles outbreak.
Read original →At a federal autism advisory committee meeting reshaped by HHS Secretary Robert F. Kennedy Jr., members openly discussed vaccines as a potential autism cause despite the debunked link. The committee approved a controversial strategic plan that shifts autism research away from genetics toward less evidence-based areas and nearly doubles federal funding.
Read original →Researchers introduce a single-atom inhibitor concept using gold to target cysteine residues on oncogenic drivers, showing efficacy in EGFR- and KRAS-mutant lung cancer models.
Read original →The FDA has approved Roivant's once-daily pill brepocitinib (Lisraya) for dermatomyositis, offering a new treatment option for a rare autoimmune disease beyond current steroid-based care.
Read original →Moderna is raising $2 billion after the Phase 3 success of its personalized cancer vaccine with Merck, whose algorithm selects 34 neoantigens per patient from thousands of tumor mutations. The vaccine could be the first approved medicine with algorithm-written genetic instructions, though details remain proprietary and some investors question whether personalization is even necessary.
Read original →This Pharmalittle roundup covers two major stories: the FDA approval of Revolution Medicines' first-in-class pancreatic cancer drug that nearly doubled median overall survival, and the Trump administration's new drug-pricing agreements with midsized biotech companies.
Read original →New documents contradict RFK Jr.'s confirmation testimony that his 2019 Samoa trip had nothing to do with vaccines, showing he wrote to Samoa's prime minister requesting to study local MMR vaccines. The controversy centers on whether he misled Congress and whether his visit contributed to a deadly measles outbreak.
Read original →Hospital leaders are launching a long-shot lobbying effort to delay or roll back nearly $1 trillion in Medicaid cuts enacted as part of President Trump's tax cut law, hoping to soften the policy and build support for a future reversal. The push has already drawn interest from some Democrats and at least one Republican, though it faces steep political and financial obstacles.
Read original →Louisiana, the only state giving 20% of opioid settlement money to sheriffs, has seen most of that spending go to law enforcement gear rather than addiction treatment. A review panel deemed 66% of the $8.1 million reported spending inappropriate, and 60% would be disallowed in other states. A few sheriffs used funds for jail-based treatment and overdose response training.
Read original →After two measles deaths in Pennsylvania, HHS Secretary Robert F. Kennedy Jr. clashed with Gov. Josh Shapiro over vaccine misinformation. Kennedy continues to downplay measles and share anti-vaccine content while urging vaccination in person, drawing pushback from the CDC and Senate leaders.
Read original →Drugmakers are racing to develop the first approved treatment for high Lp(a), a genetic cardiovascular risk factor affecting 1 in 5 people, with Novartis leading late-stage trials and billions of dollars at stake.
Read original →STAT's Morning Rounds covers new CDC data showing U.S. life expectancy at birth reached 79 in 2024, surpassing pre-pandemic levels, along with stories on removed public comments about a controversial NIH funding rule, AI-based detection of hospital drug diversion, and early impacts of Trump's Medicaid cuts.
Read original →Federal cuts to Medicaid and insurance subsidies are forcing rural health systems to prepare for major disruption. In Maine, where pressures are most acute, providers are planning service closures, consolidations, and new care-delivery models.
Read original →The FDA is preparing to issue formal regulatory guidance for medical devices that use generative AI, promising both broad and topic-specific policies. The move aims to give the health technology ecosystem long-awaited clarity on how these products will be evaluated.
Read original →The Trump administration issued a final rule barring federal Medicaid and CHIP funding for pediatric gender-affirming medications and surgery, a move experts say could set a precedent for restricting Medicaid coverage of other drugs.
Read original →Scientists are deploying Merck's Ervebo vaccine in the Democratic Republic of the Congo to help curb an Ebola outbreak that is expanding at an unprecedented rate, despite the vaccine targeting a different species of the virus.
Read original →The FDA has approved a gene therapy from Ultragenyx, marking a regulatory milestone for the company and the gene therapy field.
Read original →STAT's Pharmalittle roundup covers two notable FDA approvals: Regeneron's Pasatru for the ultra-rare bone disorder FOP, and Ultragenyx's Genglycos, the first gene therapy for glycogen storage disease type Ia.
Read original →Trump has nominated Heidi Overton, a White House domestic policy deputy, to lead the FDA. Overton has been a key behind-the-scenes health policymaker in the administration, influencing vaccine schedules and nutrition guidelines.
Read original →FDA approved Regeneron's Pasatru for fibrodysplasia ossificans progressiva (FOP), an ultra-rare disease causing abnormal bone growth. The drug aims to preserve mobility and extend survival, capping a three-decade development effort.
Read original →This Pharmalittle roundup covers two key developments: President Trump is expected to nominate Heidi Overton as FDA commissioner, and Merck and Moderna's personalized mRNA cancer vaccine slowed melanoma recurrence in a late-stage trial, potentially ushering in a new oncology approach.
Read original →A pediatrician recounts how a 12-year-old patient was sexually groomed by an AI chatbot on her school laptop, warning that these tools pose a growing risk to minors. He cites research on teen chatbot use, failures of safety rules at Character.AI, and high-profile lawsuits after AI-related teen suicide.
Read original →President Trump is expected to nominate White House domestic policy deputy director Heidi Overton to lead the FDA. The pick, if confirmed, would place a key health policy insider at the helm of the agency overseeing drugs, food, and medical devices.
Read original →Bon Secours Mercy Health, a nonprofit health system, has received $1.1 billion in payouts this year from its minority stake in medical billing firm Ensemble Health Partners, far exceeding its operating income.
Read original →Skyrocketing health care costs are forcing U.S. public-sector employers to raise taxes and cut benefits, as exemplified by Dauphin County's 22% property tax hike. The article explores how state and local governments across the country are struggling under double-digit premium increases and facing impossible choices between taxes, benefits, and worker satisfaction.
Read original →The IRS is investigating UnitedHealth over its tax filings from 2017–2020, seeking to significantly increase taxable income, and the company may face additional payments for later years. The probe could carry major financial consequences for the nation's largest health insurer.
Read original →Researchers designed and validated CRISPR guide RNAs that target the two main BRAF driver alterations in pediatric low-grade glioma: the KIAA1549-BRAF fusion and the BRAF V600E point mutation. The approach achieved high editing rates in patient-derived and model cell lines, supporting a potential one-time gene-editing therapy.
Read original →The FTC and state attorneys general are investigating Epic Systems, the largest U.S. electronic health records vendor, for potential antitrust violations involving employee non-compete agreements and use of its market dominance to block rivals from patient data. The probe is early-stage and may not result in charges.
Read original →Luigi Mangione pleaded guilty to federal stalking charges in the killing of UnitedHealthcare CEO Brian Thompson, admitting he shot Thompson in 2024. He faces a potential life sentence, with sentencing set for Dec. 18. His lawyers are seeking to dismiss a separate state murder case on double jeopardy grounds.
Read original →This STAT+ newsletter covers three biopharma developments: the FDA's accelerated approval of Bristol Myers Squibb's oral multiple myeloma drug Zenbexus, PBMs agreeing to display TrumpRx drug prices, and Novartis winning a U.K. patent fight over Entresto. The Zenbexus approval marks a new class of treatment and the first use of a more sensitive remission measure by U.S. regulators.
Read original →STAT's Pharmalittle roundup covers the FDA approval of Bristol Myers Squibb's Zenbexus, a first-in-class CELMoD therapy for advanced multiple myeloma, and an appeals court ruling reviving a $6.7 billion shareholder lawsuit against BMS over delayed drug approvals.
Read original →A new CMS rule barring federal Medicaid and CHIP coverage for pediatric gender-affirming medications and surgery takes effect Oct. 13, and legal experts say it may be harder to challenge than previous administration actions. The rule follows a string of court losses for the Trump administration, but Massachusetts has already promised a lawsuit.
Read original →Two years after the 2024 federal overhaul of methadone clinic regulations, a significant majority of opioid treatment programs have implemented changes such as expanded take-home medication, leading to increased treatment retention. The article examines whether clinics truly shifted their culture from punitive to patient-centered care.
Read original →A federal appeals court sided with providers in a No Surprises Act dispute, ruling that the government's method for calculating qualifying payment amounts (QPAs) was flawed and should exclude 'ghost rates' while including bonus and incentive payments, potentially boosting arbitration payouts.
Read original →The Trump administration unveiled a new 'treatment first' addiction toolkit that emphasizes faith-based interventions, abstinence, and employment, while rejecting harm reduction and the 'housing first' approach. The policy marks a sharp departure from Biden-era strategies and has drawn attention for its limited focus on opioid medications.
Read original →The World Health Organization has publicly criticized President Trump's executive order to reduce recommended childhood vaccines and split combination shots like MMR into single-pathogen vaccines, calling it politically motivated and based on disproven claims linking vaccines to autism. A STAT analysis suggests the order would make the U.S. an outlier, as most countries use combined MMR vaccines.
Read original →This Pharmalittle roundup covers two major pharma stories: a safety alert over deaths and severe side effects linked to Neurocrine's Vykat XR for Prader-Willi syndrome, and Eli Lilly suing companies selling black-market versions of its experimental obesity drug retatrutide before approval.
Read original →A STAT investigation reveals that Commure, a $7 billion Silicon Valley startup using AI to automate healthcare administration, offers thousands of dollars in referral compensation to customers and others who promote its products, while some customers report steep financial losses. The company defends the referral programs as industry standard and claims the vast majority of its customers are satisfied.
Read original →Physicians and Prader-Willi syndrome experts are alerting clinicians to potential safety issues with Neurocrine Biosciences' Vykat XR, citing seven reported deaths and over 100 serious adverse events since its FDA approval. The drug, approved to curb hunger in PWS patients, has not been definitively linked to these events.
Read original →The Trump administration will stop Medicaid and CHIP coverage for gender-affirming surgeries and hormone treatments for transgender minors, effective Oct. 13, with coverage for existing hormone treatments phased out by April 2027. The policy is part of a broader administration push against transgender health care and faces legal challenges from LGBTQ advocacy groups.
Read original →President Trump signed an executive order that unilaterally changes the federal vaccine schedule for children, including pushing to split the MMR shot into three separate shots. Health industry leaders, whom Trump may need for his agenda, are pushing back against the order, which lacks supporting evidence.
Read original →Skylark Bio announced it has dosed the first patient in a gene therapy trial for hearing loss caused by GJB2 mutations, as the field expands beyond the recently approved otoferlin-targeted therapy.
Read original →The FDA rejected ITM-11, a radiopharmaceutical therapy for rare gastrointestinal tumors, due to manufacturing issues, halting a potential competitor to Novartis' treatment. The drug had shown superior progression-free survival in a clinical trial.
Read original →The FDA is proposing a new rule requiring companies to notify the agency about food additives, including those already on the market under the GRAS loophole, and to make usage details public in a database. The move aims to close a decades-old information gap but stops short of requiring proof of safety for existing additives.
Read original →The FDA's advisory panel will review Grail's Galleri, a blood test designed to detect multiple cancers early. This regulatory review is a critical step for the test's potential approval and clinical adoption.
Read original →The FDA has issued an Emergency Use Authorization for CLiK Extra (dicyclanil) wound spray to prevent New World screwworm infestations in livestock, camelids, and certain wildlife species. The product acts as an insect growth regulator to halt larval development and is available over the counter.
Read original →The NIH is unveiling a redesigned website that consolidates its sprawling digital presence into eight thematic hubs, aiming to make health and research information easier to find. A beta version soft-launched this week, with some features including search not yet operational, and older sites will be sunset gradually. The overhaul follows criticism that NIH's 700+ websites created confusion, especially during Covid-19, and replaces a Biden-era consolidation plan that was scrapped under the Trump administration.
Read original →STAT+ reports that Eli Lilly is bypassing Australian pharmacies with a direct-to-consumer model, according to the headline of a newsletter roundup whose excerpt is otherwise paywalled. The same roundup notes Novartis's $575 million upfront license for an experimental mRNA autoimmune therapy from China's Abogen Biosciences and a STAT analysis finding NIH spent its $34 billion FY2026 research-grant allocation amid slower, more opaque funding processes.
Read original →STAT's Pharmalittle roundup covers a disappointing obesity-drug result from Boehringer Ingelheim and Zealand Pharma, looming changes to key Senate health committees after the midterms, and a $7.8 billion RNA-therapy licensing deal between Novartis and China's Abogen. The items signal a crowded obesity market, shifting U.S. health policy leadership, and continued big-pharma interest in Chinese RNA platforms.
Read original →A pharmacist argues that 340B orphan-drug exclusions are being applied to entire molecules rather than to the rare-disease uses that earned the designation, forcing his critical access hospital pharmacy to sell drugs like Rinvoq at a loss when prescribed for Crohn’s disease. He describes HRSA’s failed attempt to narrow the exclusion and calls for the law to catch up.
Read original →In a STAT opinion piece, an event physician recounts treating a 107°F heat-stroke patient during the record-hot 2022 New York City Marathon, where the finish-line medical tent ran short on ice, cooling tubs, electrolyte testing, and monitors despite being in Manhattan. The author argues that rising marathon participation and global temperatures make race-day heat risk a public health and preparedness problem, not just a matter of individual runner responsibility, and notes some races are already adapting.
Read original →Researchers introduce cTACs, synthetic CTLA-4-targeting chimeras that exploit trans-endocytosis to degrade PD-L1 across immune and tumor cell boundaries. The lead candidate cTAC4.0 reduces membrane-bound and soluble PD-L1, reprograms suppression into CD28 co-stimulation, and boosts engineered T cell cytotoxicity in vitro and tumor control in a glioblastoma xenograft model.
Read original →Talus Bio has developed a structure-free AI model aimed at intrinsically disordered proteins, which have been difficult to drug because they lack a stable structure to model. The approach targets these proteins in their native cellular context rather than in isolation or from predicted structures.
Read original →STAT's 'The Readout LOUD' podcast discusses why Americans have lost trust in science and how policy leaders fueled that mistrust, featuring an interview with trust-in-science reporter Nicholas Florko. The episode also covers UniQure's Huntington's gene therapy update, Beam Therapeutics' lawsuit against a Chinese competitor, and changing GLP-1 messaging from Novo and Eli Lilly.
Read original →A proposed overhaul of the CDC's National Health Interview Survey would strip out several disability-related questions, including items on hearing aids, fatigue, cognition, and mobility supports like wheelchairs and scooters, cutting the adult questionnaire from 482 to 150 questions. Disability advocates and researchers warn the redesign would worsen an already severe undercount — one recent paper estimates past surveys may have missed 75% of people with intellectual and developmental disabilities — and undermines stated federal goals of reducing chronic disease burden.
Read original →Blue Shield of California is one of 17 major health plans adopting payment models inspired by Medicare’s ACCESS Model, but details remain undecided. Its CMO said the insurer is weighing whether to adopt CMS payment amounts and which organizations to work with, and it expects similar commercial-plan models in 2027. Blue Shield serves 6 million members.
Read original →A STAT Pharmalittle roundup covers a Trump administration final rule to lower Medicare prices for physician-administered drugs and mid-stage Lilly data on a Zepbound/eloralintide obesity combination. The Medicare rule, known as GLOBE, applies to only four companies and saves 96% less than originally proposed, while the Lilly combination produced 23.3% weight loss at 48 weeks but had high discontinuation rates.
Read original →STAT’s Morning Rounds newsletter rounds up several health and biopharma developments: China’s biotech dealmaking surge, an estimated 281,000 legal immigrants at risk of losing Medicaid and other benefits, Nebraska’s Medicaid work requirements causing coverage losses, and pharma’s new top lobbyist. The item is titled as a Trump administration appeal of a ruling that blocked limits on international student visas, though the excerpt focuses on the newsletter roundup.
Read original →At a Shanghai biotech event in the 'Science City' district, executives from ascendant Chinese biotechs touted China's drug development as faster, cheaper, and more efficient than the U.S. or Europe. Abbisko co-founder Zhui Chen cited an 11-month trial for a drug licensed to Merck KGaA, which impressed Merck enough that it asked whether Abbisko could train its staff.
Read original →STAT News examines whether Eric Cantor, the former House Majority Leader, can help the pharmaceutical industry navigate Washington’s increasingly populist and anti-corporate political climate. The piece recalls Cantor’s 2013 effort to rebrand the GOP away from its image as a defender of wealthy corporate interests, raising the question of whether that playbook can work for pharma now.
Read original →HHS announced new initiatives to speed up clinical trials by using more AI and computational models and moving away from sharply delineated trial phases. The centerpiece is a five-year ARPA-H program called SURPASS, which will begin accepting ideas later this fall, though funding and participant-flexibility details were not disclosed.
Read original →A new AP-KFF poll finds about half of rural voters identify with the Make America Healthy Again (MAHA) movement, but roughly 8 in 10 say Trump administration health policies have had a negative effect or no impact on their communities' health, including 68% of MAHA supporters. The results point to a disconnect between MAHA-branded policy priorities and rural voters' perceptions, even as many prioritize health issues at the ballot box.
Read original →STAT's biotech roundup covers Beam Therapeutics alleging a Chinese company stole its IP, PhRMA naming a new leader, and Moderna appointing Juan Andres as COO as it expands into oncology. It also notes Pierre Fabre and Atara Biotherapeutics refiling Ebvallo with the FDA for an ultra-rare, fatal blood cancer in transplant recipients.
Read original →STAT's Pharmalittle roundup covers Beam Therapeutics suing a former scientist over alleged IP theft used to co-found Chinese company YolTech Therapeutics, Eric Cantor's appointment as PhRMA CEO, and the Trump administration's push on drug importation and pricing deals.
Read original →STAT’s Morning Rounds newsletter covers the MAHA movement’s corporate turn, a CDC measles death count that still differs from Pennsylvania’s, confusion over Robert F. Kennedy Jr.’s measles vaccine stance, and congressional pressure on a new prescription drug import rule. The items highlight tensions over public health messaging and drug import policy.
Read original →In a STAT News opinion piece, former Commerce Secretary Gary Locke and former Rep. Patrick McHenry argue the U.S. should strengthen its own biotech sector rather than rely on broad restrictions to contain China. They cite Beijing's new five-year plan to make biomedicine a "pillar industry" and China's rapid gains in drug development, warning that blanket measures such as tariffs on drug ingredients could weaken U.S. advantages.
Read original →At the 2025 MAHA Summit in Washington, D.C., the Make America Healthy Again movement showed a corporate shift, with health care executives and federal officials sharing the stage and industry leaders promoting their work under the MAHA banner. A panel on affordability featured UnitedHealth and Elevance executives touting AI and defending prior authorization, illustrating how a movement born from mistrust of corporate influence is now embracing it.
Read original →A growing group of congressional lawmakers is urging the Trump administration to reconsider a federal rule taking effect next month that would require medicines mailed from abroad to clear customs through a licensed broker and an entry bond, potentially cutting off a longstanding route for Americans buying cheaper prescriptions from Canada and overseas. The rule adds new cost and complexity to personal drug imports, which are already largely illegal unless the medicines are FDA-approved.
Read original →Beam Therapeutics is suing former scientist Zi Jun "Emma" Wang and Chinese biotech YolTech Therapeutics, alleging she stole intellectual property from Beam’s lab notebooks to co-found YolTech. YolTech and Serapha Bio—a new startup formed with RA Capital and RTW—are named defendants, against a backdrop of rising US-China biotech tensions.
Read original →STAT reports that Heidi Overton, nominee to lead the FDA, will not get a Senate health committee vote before the midterm elections, as the Senate leaves for recess until Nov. 9; the delay leaves her confirmation uncertain. The newsletter also flags a Medicaid drug-pricing pilot deadline, a Wednesday committee vote on other HHS nominees, CMS Administrator Mehmet Oz’s CHOICE push, and an alcohol policy conference.
Read original →Anthropic is joining ARPA-H's clinical AI moonshot and plans a closed-door health care event, according to STAT. The move expands Anthropic's health care push even as the company warns about AI catastrophe risks and regulation remains unsettled.
Read original →STAT's Pharmalittle roundup covers Novo Nordisk's up-to-$2.6 billion licensing deal for a weekly oral obesity candidate from China's Hengrui Pharma and Roche's decision to halt an obesity drug after trial data missed internal targets. The item also flags Merck pulling an antibiotic, though the excerpt gives no further details on that.
Read original →STAT News reports that researchers slowed neurodegeneration in mice by preventing T cells from entering the brain, a preclinical finding with potential implications for Alzheimer's and other neurodegenerative diseases. The accompanying STAT Morning Rounds newsletter also covers an AI discovery-credit controversy, rising Ebola/measles/dengue outbreaks, and a Supreme Court appeal over gender-affirming care in federal prisons.
Read original →Sociologist Jennifer Reich, who has studied vaccine-hesitant families for two decades, argues their decisions are often logical responses to cultural pressures that ask parents to be informed consumers and focus on their own child's health rather than collective responsibility. STAT interviews her ahead of its summit and amid a Pennsylvania measles outbreak, challenging the selfish/anti-science narrative.
Read original →STAT News previews how the November midterm elections could reshape federal health policy, including Medicaid funding and drug pricing, especially if Democrats win a chamber of Congress. The analysis draws on interviews with nearly a dozen health industry leaders and lobbyists to outline the policy questions that will affect patients, science, and the health system.
Read original →In a STAT News opinion piece, pediatricians Tina L. Cheng and James M. Perrin and retired Gen. Stanley McChrystal argue that declining child health is the shared root cause of U.S. problems including military recruitment shortfalls, workforce shortages, rising health care costs, and weakened global competitiveness. They cite data showing 77% of young Americans cannot qualify for military service due to health issues, U.S. children are 1.8 times more likely to die than peers in other industrialized countries, and four in 10 will reach adulthood with chronic conditions. The authors call for treating child health as a national security priority rather than a separate issue.
Read original →STAT’s Pharmalittle newsletter highlights Novo Nordisk and Eli Lilly repositioning GLP-1 drugs from obesity treatments to broader lifestyle/look-and-feel products as insurance coverage stalls, and a second setback for Merck and Daiichi Sankyo, which withdrew a U.S. accelerated approval application for an experimental small cell lung cancer therapy after FDA said mid-stage data were insufficient. The withdrawal is the second pullback under their cancer alliance.
Read original →STAT's roundup leads with the Trump administration clawing back nearly $1 billion in congressionally approved HHS spending through a "pocket rescission," targeting immigrant- and diversity-focused health programs. It also covers Novo Nordisk's shift toward lifestyle-style GLP-1 marketing and expert pushback on Anthropic's claim that Claude found a CRISPR-like gene system.
Read original →STAT reports that blockbuster GLP-1 obesity drugs are being marketed less as medical treatments for 'patients' and more as lifestyle or weight-loss products for 'customers,' with Novo Nordisk leading the shift. The rebranding of Wegovy and consumer-style slogans like 'Live lighter' and 'Summer Glow Up' signal a broader commercial reframing of obesity medicines.
Read original →A bioRxiv study tested AAV-mediated human TBR1 gene supplementation in Tbr1-haploinsufficient mice, a model of a neurodevelopmental disorder with intellectual disability and autistic features. Neonatal treatment increased TBR1 and selected neuronal markers, improved social and olfactory behaviors, and partially normalized EEG abnormalities, though anterior commissure defects and some EEG/sleep changes persisted. The results support further development of TBR1 gene supplementation and suggest social-interaction EEG modulation as a possible treatment-response measure.
Read original →Nektar Therapeutics shares ended Friday roughly flat, down 4% to $57.06, even after a jury ruled in its favor against Eli Lilly in a dispute over Lilly's termination of their rezpegaldesleukin collaboration. The $90 million verdict came in below what Nektar sought, muting the stock reaction.
Read original →An opinion piece by a CDC investigator reflects on the 2001 anthrax letter attacks 25 years later, when contaminated mailings from New Jersey caused 22 cases and five deaths. The author argues the episode's lessons—especially how agent formulation and dissemination route shaped disease patterns—should inform preparedness for future intentional or inadvertent biothreats.
Read original →The U.N.-backed Medicines Patent Pool has signed sub-licensing agreements with 11 manufacturers to produce generic versions of Roche's influenza drug Xofluza for 129 low- and middle-income countries, aiming to bolster pandemic preparedness. The deals include technical data, reference products for bioequivalence testing, and regulatory support to widen affordable access.
Read original →An opinion piece by the CEO of Reproductive Futures criticizes FDA commissioner nominee Heidi Overton for evading questions about mifepristone and warns her anti-abortion views could threaten access to the drug. It argues that mifepristone has a strong safety and efficacy record despite decades of political and regulatory scrutiny, and that burdensome FDA restrictions also block its use for miscarriage care.
Read original →STAT's Pharmalittle roundup covers FDA commissioner nominee Heidi Overton's Senate hearing, where she declined to take clear positions on vaccines, mifepristone, and China, and Novo Nordisk's deal worth up to $1.3 billion to license Nanexa's drug-delivery technology for longer-acting obesity and diabetes injections. The Novo agreement aims to reduce injection frequency to monthly or quarterly dosing.
Read original →The newsletter's lead item reports that a federal judge rolled back landmark disability protections, though the excerpt provides no further details. It also covers FDA commissioner nominee Heidi Overton's Senate hearing, Chris Klomp's committee approval to become HHS deputy secretary, and NIH's new PubMed 'Linked Discoveries' feature.
Read original →A STAT opinion piece examines the renewed "died with" vs. "died of" debate after Pennsylvania reported measles-associated deaths that the CDC initially omitted from its national count. It explains how U.S. death certificates establish causal chains and argues that the measles deaths should be classified as caused by measles, not merely occurring alongside it.
Read original →Heidi Overton, President Trump’s nominee to lead the FDA, faced senators in a confirmation hearing on topics including China, vaccines, and abortion access, but repeatedly declined to reveal her own positions. She pointed to existing FDA guidance and approvals for childhood vaccines and mifepristone without saying whether she would update them, drawing criticism from Sen. Chris Murphy.
Read original →A STAT News biotech podcast/readout item announcing a new episode of The Readout LOUD, featuring Jason Mast from Shanghai on the rise of Chinese drug development and a discussion with Margaret Manto about Heidi Overton, the president's nominee for FDA commissioner. It also profiles STAT's biotech reporters and points to further reading on Overton, the ITM/Telix merger, and osteoporosis.
Read original →Altruist Biologics’ Suzhou manufacturing site has received EMA GMP certification. The company says its Quality Risk Management framework supported compliance risk identification, cross-regional technology transfer, and predictability as therapies move toward regulatory submission and commercialization.
Read original →The Senate Finance Committee advanced Chris Klomp’s nomination to be HHS deputy secretary in a 15-12 vote, sending it to the full Senate. Klomp, currently a senior adviser to HHS Secretary Robert F. Kennedy Jr., has already helped broker drug pricing deals and manage personnel, and his confirmation hearings focused on his influence over vaccine policy and Medicare payment issues. The committee also advanced Ge Bai to be HHS assistant secretary for planning and evaluation.
Read original →STAT+ reports that Kyverna’s cell therapy showed lasting benefit in autoimmune disease, though the item is a paywalled teaser without trial details. The same biotech roundup notes an FDA advisory committee backed Grail’s cancer blood test and that Gilead is betting on autoimmune drug data.
Read original →STAT's Pharmalittle roundup highlights the upcoming Senate hearing for FDA commissioner nominee Heidi Overton, who plans to stress FDA speed and efficiency to compete with China's biotech sector, and reports that several states remain undecided about the Trump administration's GENEROUS Medicaid drug pricing model despite officials' claim that all states agreed to participate. The roundup also references a Lilly partnership in China, though the excerpt gives no details on that item.
Read original →Gilead Sciences executives are publicly emphasizing the company’s push into inflammatory and autoimmune diseases, with CFO Andy Dickinson calling immunology one of Gilead’s three core scientific focus areas at a recent investor conference. The comments highlight Gilead’s effort to build a third business leg beyond virology and oncology.
Read original →A STAT+ analysis examines how radiology practices are adopting AI, blurring the line between technology development and clinical practice. It revisits Geoffrey Hinton's prediction that AI would replace radiologists within a decade, noting that deadline has passed while outpatient and teleradiology groups increasingly build, buy, and deploy AI in-house.
Read original →STAT News reports that Flagship Pioneering has secured a Pentagon contract. The newsletter also covers European drugmakers urging higher government payments and a surge in VC investment in osteoporosis drugs following new FDA guidance.
Read original →This STAT Morning Rounds newsletter roundup covers several health-policy and pharma developments: new FDA/NIH moves away from animal testing, Medicare's GLP-1 demonstration enrolling 700,000 seniors, renewed industry interest in osteoporosis drugs after a new FDA endpoint, and Quorum Health's conversion from private-equity ownership to nonprofit status.
Read original →Drugmakers and biotech venture capitalists are showing renewed interest in osteoporosis treatments, encouraged by a long-awaited regulatory change. The field had been deprioritized because of burdensome dosing requirements and safety concerns, leaving many eligible patients untreated. Eli Lilly is recruiting osteoporosis scientists, and other companies and VCs are reportedly following suit.
Read original →A STAT News opinion essay argues that women with severe mental illness are under-supported in motherhood and reproductive psychiatric care, drawing on the author's own history and the Lindsay Clancy postpartum psychosis case. It cites statistics on SSRI use in pregnancy and care gaps to show why reproductive psychiatry needs more attention.
Read original →STAT+ reports that Novo may secure more favorable terms than expected under Medicare’s Bridge program, a development with implications for drug pricing and biopharma payment models. The same biotech roundup also covers positive clinical updates from Roche, Celldex, Ionis, and Viking.
Read original →STAT News' Morning Rounds is headlined by a report that the new head of a federal autism committee has financial ties to leucovorin, an autism-related drug. The provided excerpt is a newsletter roundup that also covers teen social media bans, an AI medical-ethics study on kidney allocation, and congressional pushback against political appointees reviewing NIH grants.
Read original →Australia, Indonesia, and the EU have introduced or are pursuing social media bans for minors, while Meta agreed to pay up to $18 billion over claims that Facebook and Instagram harmed children and will add safety-by-design features. A STAT opinion argues researchers must independently evaluate whether these restrictions improve teen mental health, noting effects will likely vary and early Australian evidence shows age verification is difficult and benefits are unclear.
Read original →STAT profiles the Ohio governor’s race between Democrat Amy Acton, the physician who led Ohio’s aggressive Covid-19 response, and Republican Vivek Ramaswamy, the biotech founder and former presidential candidate. The contest is framed as a test of heartland opinion on the Covid legacy, trust in science, and health care affordability, with ACA enrollment in Ohio down by one-third after federal subsidies expired.
Read original →A cancer clinician argues that evidence-based integrative oncology treatments—such as acupuncture, mindfulness, exercise, and nutrition counseling—are supported by major guidelines but remain inconsistently covered by insurance. The piece frames this as a policy failure rather than a scientific one and calls for coverage decisions to follow ASCO/SIO and NCCN recommendations.
Read original →At its Capital Markets Day, Novo Nordisk outlined a 2030 strategy to launch more than five multi-blockbuster drugs per year and generate over DKK 150 billion ($23 billion) in risk-adjusted pipeline sales by 2035. The plans failed to impress investors, highlighting concerns about the company's growth trajectory.
Read original →A STAT Pharmalittle roundup reports that Novo Nordisk, seeking to reassure investors after concerns about overreliance on GLP-1 drugs, plans at least five multi-blockbuster launches by 2030 and more business development outside diabetes and obesity. It also highlights early Phase 1 data from Alkermes showing its orexin agonist ALKS 7290 was well tolerated and produced a 19-point ADHD symptom reduction at a 50 mg dose over two weeks.
Read original →A STAT Morning Rounds newsletter leads with President Trump's latest vaccine "demands," which repeat previously debunked misinformation, and also covers a simpler way to collect drug-safety data during pregnancy, RFK Jr.'s midterm campaigning, and a growing kratom withdrawal crisis. It closes with a reporter's personal essay on why people become skeptical of the health system.
Read original →Novo Nordisk used its capital markets day to outline a new strategy to regain momentum, including launching at least five multi-blockbusters by 2030, expanding beyond diabetes and obesity, and selling some products more like consumer goods. CEO Mike Doustdar said Novo will be more active in business development, but the shares fell 5% as investors wanted more specifics.
Read original →In a STAT opinion piece, Reed Jobs argues the NIH budget should be $100 billion per year, citing the FDA approval of Revolution Medicines' daraxonrasib for previously treated KRAS-mutant pancreatic cancer as proof of the value of biomedical research. The drug nearly doubled survival in a clinical trial and is described as the first therapy to successfully target KRAS.
Read original →The Jehovah’s Witnesses have partly eased their long-standing ban on donated blood, allowing members to accept blood-derived products and treatments using the four main blood components—plasma, platelets, and red and white blood cells—while still prohibiting whole-blood transfusions. The change, announced Friday, is the group’s second policy revision this year and marks a notable shift in a controversial teaching that critics say has led to preventable deaths.
Read original →STAT+ reports that Roche is expanding its Boston footprint with a new research center, highlighting continued investment in the Boston area. The accompanying biotech newsletter excerpt also flags the first gene therapy approval for Sanfilippo syndrome, mixed news for Xenon Pharma, a rare gene variant tied to heightened lung cancer risk in non-smokers, and an upcoming confirmation hearing for the nominee to lead the FDA.
Read original →A plastic surgeon's STAT opinion piece describes a rise in young men seeking cosmetic procedures, driven partly by social media influencers and looks-based economic incentives. The author cites 2024 U.S. data showing men had 1.6 million minimally invasive and nearly 100,000 surgical cosmetic procedures, as men become the fastest-growing aesthetics population.
Read original →A STAT opinion piece argues that 'Asian glow'—alcohol flushing common among people of East Asian descent—is a visible sign of inherited ALDH2 deficiency, not a harmless quirk. The physician-author says clinicians should counsel affected patients about acetaldehyde accumulation, immediate symptoms, and elevated long-term risks including upper digestive tract cancers, especially for heterozygous ALDH2*2 carriers who can keep drinking.
Read original →A bioRxiv study shows that adapter CAR-T cells redirected with antibody-derived adapters against CD19, CD20, and CD38 can overcome antigen heterogeneity in B-cell lymphoma, controlling a heterogeneous Burkitt lymphoma model in vitro and in vivo. The findings support combinatorial pan-B-lineage targeting as a flexible strategy against antigen-negative relapse, while noting CD38-directed fratricide among CD38+ CAR-T cells.
Read original →Health Secretary Robert F. Kennedy Jr. announced a new ARPA-H-administered effort to speed autism diagnosis and improve quality of life by soliciting technology-based “solutions,” though grant funding details were not disclosed. The announcement, made at an anti-vaccine group’s conference, comes amid long assessment wait times, insurer pullback from a main autism therapy, and researcher wariness over Kennedy’s vaccine and Tylenol claims and dehumanizing language.
Read original →STAT's Morning Rounds newsletter bundles several developments: the FDA is still unable to refill its ranks more than a year after DOGE cut 3,500 workers, Stanford researchers have grown human brain organoids inside mice to create neuro-chimeric animals, and senators pressed Chris Klomp on whether he would stand up to RFK Jr. as HHS deputy. The issue is led by a study arguing that purer fentanyl will not solve the U.S. overdose death crisis.
Read original →STAT's Pharmalittle roundup reports that FDA hiring is being slowed by bureaucratic delays tied to DOGE cuts, leaving prospective employees in pre-onboarding limbo, and that Bavarian Nordic has named former Sanofi executive Tarja Stenvall as CEO after a failed takeover bid triggered leadership turnover.
Read original →House Ways and Means Republicans advanced a party-line bill that would change how MedPAC studies Medicare Advantage spending, directing the nonpartisan adviser to examine overpayments in a manner more favorable to insurers. The move comes as Medicare Advantage plans face scrutiny over their cost to taxpayers; MedPAC estimated this year that Medicare pays 14% more per enrollee, or $76 billion total, for MA plans than traditional Medicare.
Read original →Democrats are pledging aggressive congressional oversight if they win either chamber in November’s midterms, with health care issues such as President Trump’s drug pricing deals as potential targets. The article explains how oversight can serve political messaging and, if Democrats flip a chamber, give them subpoena power to compel testimony from administration and company executives, though the administration could push back.
Read original →Medicare is expanding its ACCESS model, a pilot that pays approved companies to use technology to manage chronic conditions, adding substance use disorder, heart failure, COPD, tobacco use, and longer-term musculoskeletal support to the eligible conditions. The new tracks begin in spring 2027, and officials say about three in four Medicare beneficiaries will qualify for at least one track.
Read original →STAT's Pharmalittle roundup reports that GSK has taken global rights to a preclinical multiple myeloma treatment from China's Chimagen Biosciences for up to $750 million, adding a potential first-in-class trispecific T-cell engager to its pipeline. It also covers an FDA public meeting where doctors, veterans, pharmacists, and therapists urged clear safety and access standards for psychedelic therapies amid a Trump administration push to speed development.
Read original →A former tobacco-control coalition leader draws lessons from the 1998 $200 billion tobacco settlement for states deciding how to spend the $18 billion Meta settlement. The piece warns that without restrictions, settlement funds can be diverted from prevention and public health goals, leaving programs chronically underfunded.
Read original →Novo Nordisk is rebranding to “Novo” and adopting the slogan “Lasting Health Starts Now” as part of a turnaround attempt. The Danish diabetes and obesity drugmaker has fallen behind Eli Lilly in the obesity market, and its shares are down nearly 20% over the past year.
Read original →Republican lawmakers created a $50 billion rural health fund to help hospitals cope with $1 trillion in Medicaid cuts, but the fund's implementation shifted away from direct financial relief toward new programs with spending caps and political priorities. Hospital leaders are disappointed, with some declining to participate and others skeptical it can transform rural care amid survival concerns.
Read original →A STAT News opinion columnist, a New York Giants fan, wrestles with loving football despite the brain damage it causes, citing a BMJ study that found nearly 25% of nearly 900 former players who died between 2016 and 2021 had CTE. He interviews people close to the game—high school coach Bill Courtney and former Giants defensive back Everson Walls—about whether fans are hypocrites and how to make football safer.
Read original →Transcenta Therapeutics and WuXi Biologics have partnered to accelerate commercialization of HiCB technology. Transcenta is a China-based clinical-stage biopharma with more than ten therapeutic antibody candidates and capabilities spanning biologics discovery through process development.
Read original →STAT's Pharmalittle roundup covers Novartis investors' growing scrutiny of its M&A strategy after the del-desiran failure wiped nearly $30 billion from its market value, and a report warning that 90% of widely used biologics losing patents by 2034 lack lower-cost alternatives, potentially forfeiting nearly $200 billion in savings.
Read original →This STAT+ Readout newsletter roundup reports that cancer centers continue to face persistent drug shortages that disrupt patient care, alongside other biotech news including surprising heart failure drug failures and drug reps' entrenched role in medical practice. It also highlights research finding that platinum chemotherapy can leave lasting genetic scars in children.
Read original →A boycott has been launched against the American Diabetes Association, including its journal, according to the headline. The provided excerpt, however, is a STAT Morning Rounds newsletter covering a 9/11 first-responder essay, Trump's promised $500 ACA refund checks, an FDA de novo classification for an AI heart-attack triage algorithm, and the start of an item on a platinum-based childhood cancer treatment.
Read original →In a STAT opinion piece, a New York City thoracic surgeon describes treating first responders whose cancers and other illnesses emerged years after ground zero exposure, and reflects on the 25th anniversary ceremony's new moment of silence honoring those who died from 9/11-related illnesses. Through patient stories—retired police officer John Aris and retired firefighter William Corrar—the essay argues that Sept. 11's health toll is still ongoing for responders.
Read original →The Trump administration plans to mail $500 refund checks to roughly 1 million Affordable Care Act enrollees who do not receive federal subsidies, timed just before the midterm elections and concentrated in swing states. The payments exclude tens of millions of subsidized ACA members, and it is unclear what legal authority the administration has to pay only a subset of plan holders.
Read original →STAT News reports on a new analysis examining how pharmaceutical industry gifts, meals, samples, and speaking fees to physicians may have changed behavior over time. Researchers compared a 2011 survey of medical students and residents with a follow-up survey of 283 physicians conducted two years ago, concluding the issue remains contentious.
Read original →Teijin Regenet and Shinshu University Hospital have formed a research collaboration to advance CAR T-cell manufacturing in Japan, pairing the hospital's CAR T R&D and clinical application expertise with Teijin's CDMO-derived manufacturing and quality-management capabilities.
Read original →A major Novartis shareholder, Artisan Partners' David Samra, is calling for a board shake-up after a record share slump following back-to-back trial setbacks, including a late-stage failure for a drug from the $12 billion Avidity acquisition and disappointing pelacarsen data. Separately, CMS Administrator Mehmet Oz says the Trump administration is pursuing more voluntary drug-pricing deals with pharmaceutical companies after more than two dozen agreements.
Read original →A new National Comprehensive Cancer Network survey finds U.S. cancer centers continue to face medication shortages, with all reporting at least one shortage and more than 20% facing shortages of five or more drugs. Most centers rely on workarounds to treat patients, and many say shortages have disrupted clinical trials and caused treatment delays tied to prior authorization requirements.
Read original →A STAT Morning Rounds roundup highlights tension over AI in health care: CMS head Mehmet Oz promotes 'AI-based avatars' for rural communities, while rural hospital leaders doubt the tools can offset $1 trillion in looming Medicaid cuts. It also covers a $62.7 million ARPA-H program, ADVOCATE, to develop AI agents for heart failure care and a new U.K. commission recommendation on regulating medical AI.
Read original →The Trump administration is touting AI—including AI-based avatars, concierge care, and AI nurses—as a way to save rural health care amid nearly $1 trillion in Medicaid cuts, supported by a $50 billion rural health transformation fund. Rural providers and health AI experts remain skeptical, saying the tools are expensive and unproven for cost savings; current uses like ambient scribes improve workflow but do not reduce costs.
Read original →Quel launched as what it describes as the first telemedicine venture focused on using GLP-1s to treat addiction, with services available in 41 states. The offering extends a program first tested at Caron Treatment Centers in Pennsylvania, where semaglutide's use for addiction was described as uncharted territory amid limited clinical trial evidence.
Read original →Kura Oncology is launching Caspian Therapeutics, a new biotech with $50 million in funding, to develop menin inhibitors for diabetes and other cardiometabolic diseases. The effort stems from animal studies showing that targeting menin in leukemia research also helped control blood sugar. Caspian will use the funding to move its lead small molecule through an early-phase diabetes trial and develop a second candidate.
Read original →Oura, maker of the smart ring, has filed to go public and reported $1.2 billion in earnings. The filing is one item in a health tech roundup that also notes the FDA losing another key digital health leader.
Read original →NewBiologix and Synastra announced a partnership to advance rAAV manufacturing for Duchenne muscular dystrophy gene therapy, combining their respective platform technologies.
Read original →An 88-year-old cancer patient at Dana-Farber faces disruption when his Medicare Advantage plan, run by Mass General Brigham's insurance arm, drops Dana-Farber from its network on Oct. 1, highlighting a clash between top Boston hospitals.
Read original →An opinion piece argues that standard, 'boring' public health data processes are being politicized amid the measles outbreak, using disputes over counting measles deaths and false claims about vaccines to warn that trust in CDC data is eroding.
Read original →Despite a hot M&A market and expectations of a ~$20 billion takeover, French drugmaker Abivax remains unacquired, frustrating investors. The column explores possible reasons behind the stalled deal for ulcerative colitis drug obefazimod.
Read original →A physician who previously worked as a doula reflects on the difference in perspective between doulas and OB-GYNs during childbirth, arguing that both are responding to the same situation but with different priorities. The piece emphasizes the lasting importance of respectful, communicative patient care.
Read original →ARPA-H is funding biotech companies that develop custom RNA therapies, signaling U.S. government support for personalized RNA-based treatments. The specific companies and funding details are not yet disclosed.
Read original →This STAT+ article profiles a startup founded by a former ARPA-H director, centered on AI's often-overlooked 'dumb problems' in health and medicine. The provided excerpt is newsletter subscription promotion, so the article's substantive content is not included.
Read original →The American Diabetes Association's CEO shares findings from an independent review of the disruptive removals at the June Scientific Sessions, rejecting claims of viewpoint suppression and police involvement while acknowledging communication failures.
Read original →The Trump administration announced a second group of drugmakers pledged to lower drug prices to levels comparable to other nations, but the details remain undisclosed, leaving key questions about tariffs and Medicare pricing pilots unanswered.
Read original →The NIH proposed capping the number of grants a single scientist can hold to ease funding competition, but responses to the proposal are sharply divided, with 40% opposed, 27% in favor, and 32% mixed. Even some supporters worry the cap could add further disruption to researchers during a turbulent time.
Read original →A court battle between a large health insurer and Amgen is examining whether acquiring a patent application can unfairly extend a drug monopoly. The FTC has backed payers and consumers, and the outcome could intensify scrutiny of pharmaceutical patent deals.
Read original →STAT reports that GLP-1 drugs are nearly single-handedly forcing employers to rethink how they pay for workers' health care, highlighting a major cost pressure on employer-sponsored plans.
Read original →Experts in radiopharmaceuticals, led by Louise Emmett, argue that cancer patients could benefit from more frequent dosing of these targeted radiation therapies, despite safety concerns that have derailed some developers. The field has seen experimental treatments damage kidneys, liver, or bone marrow, leading to at least one company closure.
Read original →Alnylam is defending its RNAi heart disease drugs after AstraZeneca's Wainua failed a trial in ATTR-CM, arguing that its medicines retain value and that a key trial has a better design.
Read original →Hospitals are spending their political capital trying to delay or mitigate roughly $1 trillion in healthcare spending cuts that helped fund Republican tax cuts, rather than lobbying for increased payments and reduced regulation.
Read original →Biomanufacturing's reliance on steam sterilization is becoming a major bottleneck to scaling up. The article explores how alternative sterilization technologies could cut capital costs, speed plant construction, and unlock industrial biotechnology at larger scales.
Read original →An interview with Insitro founder Daphne Koller on how artificial intelligence can be used to speed up clinical trials, a key bottleneck in drug development.
Read original →A Pharmalittle news roundup covers a new survey showing U.S. employers dropping GLP-1 drug coverage due to rising costs, and a report that Massachusetts' biotech workforce shrank for the first time since 2002.
Read original →Digital health company Sword Health, known for its AI-powered virtual physical therapy, plans to acquire mental health company Headspace. The cash deal, disclosed in a regulatory filing, is expected to close Sept. 14; terms were not disclosed.
Read original →MassBio's latest annual snapshot shows a 3.9% decline in Massachusetts R&D biopharma jobs in 2025, driven by pipeline reprioritization at large companies and contraction at smaller firms, with a mid-year dip that began recovering by Q4.
Read original →A new Massachusetts Biotechnology Council report shows the state's biopharma workforce fell by about 3,600 jobs in 2025, the first decline since at least 2002, amid industry headwinds and funding uncertainty.
Read original →STAT's Health Care Inc. newsletter reports on Aon's grim prediction for 2027 job-based health premiums and teases an exclusive on the financial squeeze facing public-sector health plans, along with a union-hospital conflict.
Read original →An opinion piece examines the paradox of treatment for high-achievers like Lil Nas X, who fear that psychiatric medication will dull the very creativity and drive behind their success, and contrasts that fear with research showing untreated bipolar disorder leads to worse outcomes.
Read original →An opinion piece argues that as traditional global health aid collapses, faith-based organizations and capital generated through religious obligations represent an underused financing mechanism. It highlights nearly $2 billion in new U.S. funding for faith-based groups and the author's own initiative channeling zakat into maternal health.
Read original →This STAT News article examines what Epic Systems revealed—and notably omitted—about its AI strategy during its annual meeting, offering insight into the EHR giant's messaging on artificial intelligence.
Read original →An opinion piece argues that AI is creating a 'shadow medical system' where patients rely on consumer AI tools for health advice, diagnostics, and prescriptions, driven by financial incentives and hype about AI outperforming doctors. It warns that evidence from controlled studies is being used to market AI as a replacement for clinicians, raising regulatory and safety concerns.
Read original →GenBio AI has unveiled AIDO Cell, a virtual cell system that aims to predict how the entire molecular machinery of a cell behaves, enabling simulations of gene knockouts or drug effects. The tool, described as a 'Google Earth for cells,' could accelerate biomedical research by allowing scientists to explore cellular changes in silico.
Read original →Sanofi is laying off 229 workers in Massachusetts, all tied to Blueprint Medicines, the biotech it acquired for $9.1 billion in 2025. The move signals post-acquisition restructuring at one of the state's largest pharma employers.
Read original →AstraZeneca halts a late-stage trial of volrustomig plus chemo in non-small cell lung cancer after an independent committee found it unlikely to meet survival endpoints, while new CPI data show U.S. prescription drug prices fell 3.1% year-over-year, the steepest annual drop in over six decades.
Read original →A pediatrician argues that paid paternity leave should be viewed as pediatric preventive care, citing evidence that fathers' early involvement benefits children's development, maternal mental health, and fathers' own caregiving biology. The piece highlights that only about a quarter of American workers have access to paid family leave.
Read original →Epic Systems' annual meeting comes as the electronic health records giant faces antitrust lawsuits, AI strategy questions, a leadership exodus, and government investigations into its business practices.
Read original →Researchers developed a bispecific antibody that blocks TGFBR2 specifically on fibroblasts, using insights from a parasitic worm protein. The antibody shows cell selectivity and enhanced potency, offering a path to safer TGFβ-targeted therapies for cancer and fibrosis.
Read original →The president of the American Academy of Pediatrics argues that federal leaders are spreading misleading vaccine claims, and explains how pediatricians are countering this with evidence-based reassurance to parents.
Read original →An opinion piece argues that the U.S. and U.K. health systems, despite seeming opposites, share a fundamental flaw: they prioritize hospital-based clinical care over community-based relational support and prevention. This bias is unsustainable given aging populations, rising costs, and growing loneliness.
Read original →A GEN webinar titled 'Advancing Brain Organoids from Research Models to Scalable Platforms' features Ottimo Pharma's Joseph Shultz and Asimov's Imroz Ghangas discussing strategies for high-performing clonal titers and advancing a dual-paratopic cancer immunotherapy from sequence to dosed patient in under a year. The excerpt focuses on the immunotherapy development and manufacturing workflow rather than specific brain organoid findings.
Read original →STAT's "The Readout LOUD" podcast discusses a court decision giving international researchers a reprieve on foreign student visas, even as many scientists still consider leaving the U.S. for opportunities elsewhere and the implications for American medical research. The episode also covers Definium's new psychedelics data and what it could mean for the field.
Read original →STAT+ reports that a new startup plans to test a psychedelic-like drug against a Parkinson’s symptom. The story appears in a biotech newsletter that also notes complications in the FDA’s hiring push and research involving mice with half-human brains, but the full article is paywalled.
Read original →A public health communications consultant argues that pro-vaccine advocacy has become too somber and defensive, contrasting the celebratory 1955 polio vaccine announcement with a dour 2026 press conference on flu, Covid-19, and RSV vaccine safety. The op-ed calls for rediscovering joy, optimism, and community in vaccine messaging, pointing to Children's Health Defense as a model for movement-building despite its dangerous misinformation.
Read original →This GEN opinion piece argues that there is no universal manufacturing model for autologous cell therapies, since each program must match its production approach to local healthcare infrastructure, logistics, and market conditions. It matters because manufacturing—not science—is often the bottleneck that determines whether patient-specific therapies can scale commercially.
Read original →STAT publishes an AMA CEO John Whyte opinion essay arguing AI should augment rather than replace physicians, rebutting Ezekiel Emanuel's view. Whyte says debates over whether AI can outperform doctors miss the harder question of which medical tasks should be automated, because medicine involves judgment, communication, and individualized care beyond benchmarks.
Read original →A letter published by STAT First Opinion pushes back on a proposal to merge M.D. and D.O. education, arguing that osteopathic training's distinct 'cognitive architecture' is worth preserving. The response notes that D.O. students face real bias in residency placement but says the solution is not to abandon osteopathic principles, which are resonating with a growing share of U.S. medical students.
Read original →New York's new medical aid-in-dying law, with its unusual audio/video recording requirement, raises a philosophical question: does offering the option of death inadvertently make life feel like a burden? Drawing on philosopher David Velleman, the author argues that simply having a choice can harm autonomy, even if never exercised.
Read original →In a GEN Thought Leader article, Thermo Fisher Scientific's Augustė Užuotaitė argues that the next big innovation in biotech will come not from smarter AI software alone, but from the physical inputs—robust assay design, reagent chemistry, and consumables optimized for automation.
Read original →This opinion piece compares the use of telematics in auto insurance to the growing push for wearable health data in health insurance, arguing that promises of savings and empowerment mask privacy risks and an individualistic approach to health. It cites lack of evidence for cost savings and highlights existing insurance programs that already reward 'good' behaviors.
Read original →
